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Summary 
Cerebral small vessel disease (SVD), a main cause of ischemic stroke leading to cognitive decline 
and vascular dementia, is recognized as a considerable health care problem in aging societies. 
However, mechanisms underlying this disease are poorly understood and no specific and 
preventive treatment options are available. Several monogenic forms of SVD have been identified 
which share a number of clinical and pathological features with the sporadic disease. They are thus 
considered as valuable model diseases to understand SVD pathomechanisms. One of these 
inherited forms is the rare disease CARASIL (Cerebral Autosomal Recessive Arteriopathy with 
Subcortical Infarcts and Leukoencephalopathy), which is caused by loss-of-function mutations in 
the gene encoding the serine protease high temperature requirement protein A1 (HtrA1). HtrA1 
has been proposed to inhibit transforming growth factor beta (TGF-β) signaling by degrading 
pathway components. Evidence indicating increased TGF-β activity in CARASIL brain vessels led to 
the hypothesis that TGF-β plays a critical role in CARASIL development. The goal of this thesis was 
to provide further experimental evidence for this hypothesis using an HtrA1-deficient mouse model 
and patient fibroblasts. Newly created HtrA1-/- mice were found to be viable and fertile and 
displayed a normal life expectancy. Even though HtrA1-deficient mice did not show CARASIL-typical 
extraneurological manifestations such as spondylosis and alopecia, evidence for white matter 
changes and a reduction of vessel marker proteins were detected indicating the presence of 
pathological alterations similar to those observed in CARASIL patients. Investigation of TGF-β 
signaling in mouse brain tissue and embryonic fibroblasts (MEF) provided evidence for a decreased 
TGF-β activity upon HtrA1 deficiency. This finding was substantiated by results from human skin 
fibroblasts of two CARASIL patients suggesting a facilitative role of HtrA1 in TGF-β signaling. This 
observation contrasted with previous studies showing the opposite effect, but was in agreement 
with the identification of latent TGF-β-binding protein (LTBP-1), a well-described regulator of TGF-β 
bioactivity, as a novel HtrA1 substrate. LTBP-1 processing possibly results in a release of mature 
TGF-β from the extracellular matrix (ECM). Using HtrA1-deficient and wild-type MEF cells this study 
helped to further establish LTBP-1 as an HtrA1 target under endogenous conditions with a putative 
role in CARASIL pathogenesis. The results obtained from these analyses have deepened our 
knowledge about the role of HtrA1 in TGF-β signaling and suggest TGF-β pathway as a target for 
therapeutical intervention in CARASIL.  
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Zusammenfassung 
Die zerebrale Mikroangiopathie, eine Hauptursache ischämischer Schlaganfälle und somit 
kognitiver Störungen und vaskulärer Demenz, wird als ernsthaftes Problem des Gesundheitswesens 
alternder Gesellschaften angesehen. Bisher sind die der Krankheit zugrundeliegenden 
Mechanismen noch wenig verstanden und weder spezifische noch vorbeugende Behandlungsmaß-
nahmen bekannt. Mehrere monogene Formen der zerebralen Mikroangiopathie sind identifiziert 
worden, die eine Reihe von klinischen und pathologischen Symptomen mit der sporadischen Form 
gemeinsam haben. Sie werden deshalb als wertvolle Modellerkrankungen zur Aufklärung der 
zugrundeliegenden Pathomechanismen angesehen. Eine dieser vererbbaren Formen ist die seltene 
Erkrankung CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy), die durch Funktionsverlust-Mutationen im Gen der Serinprotease HtrA1 
(high temperature requirement protein A1) verursacht wird. Mehrere Studien deuten darauf hin, 
dass HtrA1 den Transforming Growth Factor beta (TGF-β)-Signalweg inhibiert, indem es 
Signalwegmoleküle abbaut. Aufgrund einer erhöhten TGF-β-Aktivität in Gehirngefäßen von 
CARASIL-Patienten wurde die Hypothese aufgestellt, dass TGF-β eine entscheidende Rolle im 
Krankheitsverlauf von CARASIL spielen könnte. Das Ziel der vorliegenden Arbeit war es, weitere 
experimentelle Beweise für diese Theorie zu finden. Hierfür wurden sowohl HtrA1-defiziente 
Mäuse als auch Fibroblasten aus Patienten verwendet. Wir konnten nachweisen, dass unsere neu 
generierten HtrA1-/- Mäuse sowohl lebensfähig und fertil sind als auch eine normale 
Lebenserwartung haben. Auch wenn HtrA1-defiziente Mäuse keine CARASIL-typischen 
extraneurologischen Merkmale wie Spondylose oder Alopezie zeigten, haben wir dennoch 
Anzeichen für Veränderungen in der weißen Hirnsubstanz und für eine Reduktion von 
Gefäßmarkerproteinen detektieren können, was auf ähnliche pathologische Veränderungen wie in 
CARASIL-Patienten hindeutete. Untersuchungen des TGF-β-Signalweges in Mausgehirngewebe und 
embryonalen Fibroblasten (MEF) haben eine verminderte TGF-β Aktivität bei HtrA1-Defizienz 
ergeben. Dieser Befund wurde durch Ergebnisse aus humanen Hautfibroblasten zweier CARASIL-
Patienten bestätigt und lässt vermuten, dass HtrA1 die TGF-β-Signalwirkung verstärkt. Diese 
Beobachtung kontrastiert zwar mit früheren Studien, die den gegenteiligen Effekt zeigten, steht 
jedoch in Einklang mit der Identifizierung von LTBP-1 (latent TGF-β binding protein 1), einem gut 
beschriebenen Regulator der TGF-β-Bioaktivität, als ein bisher unbekanntes HtrA1-Substrat. Die 
Spaltung von LTBP-1 führt vermutlich zu einer Freisetzung von aktivem TGF-β aus der 
extrazellulären Matrix. Durch die Verwendung HtrA1-defizienter- und Wildtyp-MEF Zellen konnte 
in der vorliegenden Arbeit eine LTBP-1-Prozessierung durch endogenes HtrA1 nachgewiesen und 
eine mögliche Rolle bei der CARASIL-Pathogenese weiter untermauert werden. Die Ergebnisse 
dieser Studie tragen zu einem tieferen Verständnis über die Rolle von HtrA1 im TGF-β-Signalweg 
bei und deuten auf TGF-β als potentielles Target für therapeutische Maßnahmen bei CARASIL hin. 
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1 Introduction 
Stroke is the third most common cause of death after cardiac infarction and cancer, and the major 
cause of acquired disability in adults worldwide (Warlow et al., 2003, Donnan et al., 2008). Besides 
Alzheimer´s disease, it represents the leading cause of cognitive impairment including dementia as 
a long term deficit (Aguero-Torres et al., 2006, Pinkston et al., 2009). Strokes can be sub-divided 
into two categories: hemorrhagic (~20 % of all cases) and ischemic (~80 %) (Figure 1.1) (Warlow et 
al., 2003). While hemorrhagic stroke results from the rupture of vessels leading to localized 
bleeding in the surrounding tissue, ischemic stroke is caused by either acute occlusion of a blood 
vessel or systemic hypoperfusion resulting in a reduced supply of brain tissue with oxygen and 
nutrients (Dirnagl et al., 1999). Together with large-artery atherosclerosis and cardioembolism, 
small vessel disease (SVD) accounts for the majority of ischemic strokes (Adams et al., 1993). 
Figure 1.1: Frequency of stroke subtypes. About 20 % of all strokes are hemorrhagic and 80 % are ischemic, with small 
vessel disease (SVD) accounting for roughly 20 % of all strokes. 
 
1.1 Cerebral small vessel disease 
The term small vessel disease comprises all angiopathies that affect the structure or function of 
small cerebral vessels including small arteries, arterioles, capillaries and small veins (Pantoni, 2010, 
Petty et al., 2000). SVD results in small infarctions in the white and/or gray matter (Wardlaw et al., 
2013), leading to the development of white matter (WM) lesions, presented as hypointense areas 
in computed tomography (CT) scans or hyperintense areas on T2-weighted magnetic resonance 
imaging (MRI) (Duering et al., 2013).  
Currently the most effective treatment to improve outcomes for acute ischemic stroke is 
intravenous administration of recombinant tissue-type plasminogen activator (tPA) (Fugate and 
Rabinstein, 2014). However, the application of this thrombolysis enzyme is highly time-dependent 
(Ozark and Jauch, 2014) and the need for alternative therapeutical approaches for SVD is immense. 
The lack of specific treatment and prevention options is largely due to the fact that the molecular 
Hemorrhagic
Ischemic
Small vessel disease
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mechanisms underlying SVD are poorly understood. Age and arterial hypertension, smoking, 
diabetes and obesity represent the main environmental risk factors for SVD (Dichgans, 2007, 
Pantoni, 2010), even though their impact might be overestimated (Wardlaw et al., 2014). But also 
genetic factors contribute to this disorder. This is reflected by several monogenic forms of SVD 
which share a number of clinical and pathological features with the sporadic disease and are thus 
considered as valuable model diseases to understand SVD pathomechanisms. The underlying gene 
defects have been identified for several of them (Table 1.1) including CADASIL (cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy), the most prevalent 
monogenic SVD, which is caused by mutations in the NOTCH3 gene (Joutel et al., 1996). CADASIL is 
characterized by progressive WM degeneration, accumulation of electron-dense granular 
osmiophilic material (GOM) and large proteinaceous deposits in blood vessel walls (Joutel et al., 
2010, Chabriat et al., 2009). 
 
Table 1.1: Monogenic cerebral small vessel diseases. CADASIL: cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy; CARASIL: cerebral autosomal recessive arteriopathy with subcortical 
infarcts and leukoencephalopathy; HTRA1 encodes the protein high temperature requirement A1; COL4A1: collagen, type 
IV, alpha 1-related cerebral small vessel disease; RVCL: retinal vasculopathy with cerebral leukodystrophy; TREX1 encodes 
the protein three prime repair exonuclease 1. Adapted from Dichgans (2007), Federico et al. (2012), Yamamoto et al. 
(2011). 
 Gene Onset Key features 
CADASIL NOTCH3  
(autosomal dominant) 
IV-V decades Recurrent subcortical cerebral 
infarctions, progressive dementia, diffuse 
WM changes, migraine with aura, GOM 
deposition. 
CARASIL HTRA1  
(autosomal recessive) 
II-III decades Recurrent small strokes, diffuse WM 
lesions, progressive dementia; scalp 
alopecia in the teen, spondylosis, 
kyphosis. 
COL4A1 COL4A1  
(autosomal dominant) 
II-IV decades Subcortical infarcts, intracerebral 
haemorrhages, diffuse WM changes and 
dilated perivascular spaces, migraines 
with/without aura, dementia; kidney 
defects. 
RVCL TREX1  
(autosomal dominant) 
IV-V decades Diffuse WM changes and lacunar strokes, 
headaches; retinal vasculopathy with 
visual loss, liver and kidney dysfunction. 
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1.2 Cerebral autosomal recessive arteriopathy with subcortical infarcts 
and leukoencephalopathy (CARASIL) 
Almost 40 years ago, a rare familial form of non-hypertensive cerebral SVD was reported in the 
Japanese population (Maeda et al., 1976). Affected persons shared clinical symptoms with CADASIL 
patients but the recessive inheritance pattern and the absence of GOMs pointed to a so far 
unidentified arteriopathy, which was initially called Maeda syndrome (Maeda et al., 1976) before 
the term CARASIL (cerebral autosomal recessive arteriopathy with subcortical infarcts and 
leukoencephalopathy) was coined in the mid-nineties (Bowler and Hachinski, 1994). As until 2010 
only Japanese patients and two patients from China had been described, CARASIL was believed to 
be restricted to the Asian population (Yanagawa et al., 2002, Zheng et al., 2009). Since then, case 
reports from Europe and India (Bayrakli et al., 2014, Bianchi et al., 2014, Diwan et al., 2012) suggest 
a more widespread distribution. To date only 60-70 patients have been reported world-wide 
(Bianchi et al., 2014). 
 
1.2.1 Clinical features 
The age of onset of encephalopathy in CARASIL patients is between 20 and 45 years (Fukutake, 
2011). Typical hallmarks are diffuse white matter abnormalities seen by T2-weighted MRI and 
multiple lacunar infarctions mainly in the basal ganglia or brain stem (Figure 1.2 A, B). Moreover, 
reduced cerebral blood flow in several areas of CARASIL brains was observed by single photon 
emission computed tomography (Fukutake, 2011). Patients suffer from stepwise deterioration of 
brain functions leading to cognitive deficits including forgetfulness, loss of sense of time, 
personality changes, emotional instability, and finally to dementia. Other neurological symptoms 
include facial palsy and gait disturbances. After occurrence of the first neurological signs, patients 
become bed-ridden and die within 10-30 years.  
One of the first indications in the vast majority of CARASIL patients is premature alopecia (diffuse 
hair loss), an extraneurological symptom developing in the second decade of life (Figure 1.2 C) 
(Nishimoto et al., 2011, Yanagawa et al., 2002). Furthermore, in the same time period when 
neurological symptoms occur, about 80 % of affected persons develop lower back pain, as a result 
of spondylosis deformans and/or disk herniation (Figure 1.2 D). Degenerative changes and 
osteoarthritis in the knee joints or elbows are also observed in some patients (Fukutake, 2011, 
Yanagawa et al., 2002). Interestingly, an association between a polymorphism in the HTRA1 gene 
and disk degeneration or spondylosis deformans was detected (Urano et al., 2010). 
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Figure 1.2: Manifestations of CARASIL. (A, B) T2-weighted MRI images of a CARASIL patient depict hyperintense lesions 
in the basal ganglia and white matter. (C) Alopecia of a CARASIL patient. (D) MRI image of spondylotic changes of the 
lumbar spine. Adapted from Hara et al. (2009). 
 
1.2.2 Neuropathology 
CARASIL-typical histopathological alterations include arteriosclerotic changes of cerebral blood 
vessels with fibrous intimal proliferation, splitting of the internal elastic membrane and hyalinosis 
of the vessel wall, resulting in luminal stenosis of small vessels in the white matter and basal 
ganglia and subsequently in WM abnormalities (Figure 1.3 B, D) (Arima et al., 2003, Federico et al., 
2012). Moreover, leukoencephalopathy detected by diffuse myelin pallor in the cerebral WM with 
relative preserved subcortical U-fibers is characteristic for CARASIL (Arima et al., 2003). Marked 
loss of arterial smooth muscle cells (SMCs) even in arteries without sclerotic changes is a hallmark 
of this disease (Oide et al., 2008) (Figure 1.3 A, B). Interestingly, Oide et al. (2008) demonstrated 
strongly decreased collagen type I, III, VI and fibronectin immunoreactivities in thinned arterial 
tunica adventitia. Moreover, they found a significantly reduced type IV collagen expression in 
CARASIL vessels that is limited to intimal endothelial cells (Figure 1.4 C, D). In the tunica media, 
remaining SMCs showed pericellular type IV collagen expression (Oide et al., 2008). Thus, a loss of 
extracellular matrix (ECM) proteins might represent an early event in CARASIL pathogenesis and 
trigger the degeneration of SMCs.  
C D A B 
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Figure 1.3: SMC and type IV collagen loss in small arteries of CARASIL patients. (A, B) Weigert and α-smooth muscle 
actin (SMA) staining; (C, D) type IV collagen staining; (A, C) nonarteriosclerotic control; (B, D) CARASIL. Medial SMCs are 
almost completely lost in narrowed lumen arteries showing splitting of the internal elastic lamina and intimal thickening 
(B). Decreased type IV collagen immunoreactivity in CARASIL arteries (D). Pericellular type IV collagen positive staining in 
ag few surviving medial SMCs is indicated by an arrow in D. Adapted from Oide et al. (2008). 
 
1.2.3 Genetics 
Consanguinity frequently seen in parents of CARASIL patients pointed to a recessive inheritance 
pattern (Yamamura et al., 1987). Recently, a genome-wide linkage analysis using microsatellite 
markers and involving eleven subjects from five consanguineous Japanese families has revealed a 
link to the 2.4-Mb region on chromosome 10q containing several genes including the high 
temperature requirement A1 (HtrA1) gene (Hara et al., 2009). As HTRA1 is expressed in bone, skin 
and vasculature, the tissues mainly affected in CARASIL, it was selected as candidate gene. 
Mutational screening discovered homozygous mutations in all patients: two nonsense and two 
missense mutations, that either lead to protein products with strongly reduced protease activity 
(A252T, V297M, R302X) or to the loss of HtrA1 expression by nonsense mediated mRNA decay 
(R370X) (Hara et al., 2009). This demonstrated the identity of HTRA1 as CARASIL causing gene. 
Subsequently, additional HTRA1 mutations in five different countries including European countries 
were reported (Bayrakli et al., 2014, Bianchi et al., 2014, Chen et al., 2013, Mendioroz et al., 2010, 
Nishimoto et al., 2011, Wang et al., 2012). The mutations mainly locate in the protease domain 
(R274Q, P285L, G295R, A321T, L364P) and likely interfere with substrate binding or the three-
dimensional structure of the catalytic pocket (Truebestein et al., 2011). This might also be true for 
A B 
100 µm 
50 µm 
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the previously uncharacterized mutation A173T (see chapter 3.4.3.3), even though it is located 
outside of the catalytic domain. Protease assays performed by our group demonstrated that this 
variant shows strongly reduced catalytic activity, however the underlying mechanism is yet 
unknown. The E42fs mutation (Bianchi et al., 2014) results in a frameshift and a premature 
translation termination. Distribution of all so far known CARASIL mutations within HTRA1 is 
indicated in Figure 1.4. 
 
Figure 1.4: Schematic representation showing HTRA1 exon (blue rectangles) organization and distribution of CARASIL 
mutations in HtrA1. Orange rectangle indicates the location of the serine protease domain. 
 
1.3 High temperature requirement A1 (HtrA1) serine protease 
The first member of the HtrA family was initially identified in E. coli (Lipinska et al., 1988) where it 
plays an important role in protein quality control. Prokaryotic HtrAs (DegP, DegS and DegQ) 
combine dual activities: on the one hand, these heat-shock proteins are chaperones refolding 
misfolded proteins at low temperatures (Spiess et al., 1999), and on the other hand, they act as 
proteases requiring elevated temperatures to degrade damaged proteins (Skorko-Glonek et al., 
1995). HtrA proteins are members of the trypsin-like serine protease family containing a serine as a 
nucleophilic amino acid at the enzyme´s active site (Clausen et al., 2011). 
Four mammalian HtrA proteins have been identified to date, HtrA1 (L56, PRSS11) (Hu et al., 1998, 
Zumbrunn and Trueb, 1996), HtrA2 (Omi) (Faccio et al., 2000, Gray et al., 2000), HtrA3 (PRSP) (Nie 
et al., 2003a) and HtrA4 (Clausen et al., 2002). While little biochemical and mechanistic information 
is available for HtrA3 and 4, the HtrA family members HtrA1 and 2 are better studied. Eukaryotic 
HtrAs are highly conserved among species (Figure 1.5 A). As HtrA1, 3 and 4 share the same domain 
architecture, as well as secretory properties and expression patterns, it is likely that they have 
related functions (Nie et al., 2003b, Tocharus et al., 2004). In contrast, the distinct protease HtrA2, 
which is known to be a mitochondrial protein with proapoptotic properties, is the only HtrA family 
member with a clear intracellular localization (Clausen et al., 2002, Li et al., 2002). However, the 
protease domain is structurally well conserved in all HtrAs. CARASIL mutations located in this 
Introduction 
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domain affect residues that are completely or largely conserved among the HtrA homologues 
(Figure 1.5 B).  
 
Figure 1.5: Domain organization of HtrA proteases and location of CARASIL mutations within the catalytic domain.     
(A) Relative positions of high temperature requirement A (HtrA) domains are taken from NCBI. Human HtrA1, 3 and 4 
share the same domain architecture including a N-terminal insulin-like growth factor-binding protein module (IGFBP; grey 
rectangle) and a Kazal-like inhibitor domain (KI; yellow rectangle) (combined these domains are called Mac25), a trypsin-
like peptidase domain (Protease; orange rectangle) and a C-terminal PDZ domain (postsynaptic density of 95 kDa, Discs 
large and zonula occludens 1; dark blue rectangle). HtrA2 lacks the Mac25 domain and possesses a N-terminal 
transmembrane anchor (TM; turquois rectangle). The PDZ domain mediates protein-protein interactions and binds to a 
short region of the C-terminus of other specific proteins (Clausen et al., 2002). (B) CARASIL mutations predominantly 
affect conserved amino acids in the serine protease domain. Sequences of human HtrA1 are shown. Conserved residues 
are shaded (dark blue, 100 % conserved; dark gray, highly conserved; gray, middle conservation; light grey, low 
conservation). The mutated amino acids are highlighted in orange. Mutations at these positions are either completely or 
mainly conserved.  
 
Human HTRA1 on chromosome 10q26 was originally identified as a gene down-regulated in SV40-
transformed fibroblasts two decades ago (Zumbrunn and Trueb, 1996). However, its X-ray crystal 
structure has been determined only recently (Truebestein et al., 2011). HtrA1 as well as other 
human HtrAs form pyramidal trimers mediated by interaction between three protease domains 
(Hansen and Hilgenfeld, 2013). In HtrA1, the catalytic triad forming the active site comprises the 
residues H220, D250 and S328 (Singh et al., 2011). Mutagenesis of serine 328 to e.g. alanine 
(S328A) results in a complete loss of catalytic activity.  
While most of the ubiquitously expressed protease HtrA1 is secreted into the extracellular space, 
about 20 % remain in the cytoplasm (Clausen et al., 2011) mainly attached to microtubules (Chien 
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et al., 2009b). An intracellular HtrA1 substrate has been identified recently: the tumor suppressor 
protein tuberous sclerosis complex 2 (Campioni et al., 2010). However, as HtrA1 is a predominantly 
secreted protease, the majority of all so far identified substrates is located extracellularly. Most of 
them are ECM proteins such as fibronectin, type II collagen, biglycan, clusterin, vitronectin, 
aggrecan, decorin and fibromodulin (An et al., 2010, Grau et al., 2006, Murwantoko et al., 2004, 
Tsuchiya et al., 2005), suggesting a role of HtrA1 in promoting extracellular matrix homeostasis. 
In addition to CARASIL, HtrA1 has also been implicated in several other disease pathologies. As it is 
down-regulated in various cancers such as melanomas, ovarian and lung cancer (Esposito et al., 
2006, Chien et al., 2009a, Shridhar et al., 2002) and as its overexpression inhibits tumor growth 
(Baldi et al., 2002), HtrA1 might function as a tumor suppressor. Furthermore, HtrA1 has been 
reported to be up-regulated in Alzheimer´s disease (Grau et al., 2005) and during osteoarthritis 
probably affecting the degradation of cartilage (Hu et al., 1998, Milner et al., 2008). Moreover, 
several studies have reported HTRA1 as a major candidate within the chromosome region 10q26 
linked to age-related macular degeneration (AMD) (Fisher et al., 2005). Finally, HtrA1 has been 
shown to play a role in cell proliferation, e.g. by processing insulin-like growth factor-binding 
protein 5 (IGFBP5) and thus releasing IGF1 to stimulate proliferation (Hou et al., 2005). 
 
1.4 Transforming growth factor beta (TGF-β) signaling 
During the past decade, a role of HtrA1 in transforming growth factor beta (TGF-β) signaling has 
emerged. It was reported to bind to various members of the TGF-β superfamily, and to attenuate 
their signaling activity in cellular reporter assays (Oka et al., 2004, Zhang et al., 2012). HtrA1-
mediated TGF-β inhibition was also observed in a chick eye differentiation model (Oka et al., 2004) 
and during maturation and survival of mouse cortical neurons (Launay et al., 2008). Since TGF-β 
signaling is crucially involved in various aspects of vascular homeostasis (see below), CARASIL 
mutations were suspected to interfere with this pathway. 
 
1.4.1 General role 
The TGF-β superfamily comprises about 40 members in humans, including the three TGF-β 
isoforms TGF-β1, 2 and 3, nodal, GDFs, activins, inhibins and BMPs (Ruiz-Ortega et al., 2007). These 
pluripotent cytokines have important roles as morphogens during embryonic development and in 
maintaining tissue homeostasis largely via transcriptional regulation of genes involved in cell 
proliferation and survival, differentiation, apoptosis, cell motility and developmental fate 
(Moustakas and Heldin, 2009, Shi and Massague, 2003).  
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Among the superfamily members the three TGF-β ligands TGF-β1, 2 and 3 are subject of an 
elaborate synthesis and activation mechanism. They are synthesized as dimeric precursor 
molecules that undergo proteolytic processing in the Golgi apparatus by furin-like convertases 
(Figure 1.6). The proteolytic fragments, the N-terminal latency associated peptide (LAP) and the 
C-terminal mature peptide (Dubois et al., 1995, ten Dijke and Arthur, 2007), remain attached 
through non-covalent bonds forming the small latency complex (SLC), in which the receptor-
binding site of mature TGF-β is sequestered by LAP (Annes et al., 2003). After covalent association 
with a member of the latent TGF-β binding protein family, LTBP-1, LTBP-3 or LTBP-4, the so-called 
large latency complex (LLC) is secreted (Saharinen et al., 1996, Saharinen and Keski-Oja, 2000). 
LTBPs mediate LLC attachment to the extracellular matrix by association with ECM proteins such as 
fibronectin and fibrillin-1 leading to the storage of latent TGF-β in the matrix (Isogai et al., 2003, ten 
Dijke and Arthur, 2007). TGF-β activation can be mediated by several mechanisms including 
cleavage of LTBPs by plasmin (Sato and Rifkin, 1989), matrix metalloproteases MMP-2 and MMP-9 
(Yu and Stamenkovic, 2000) or BMP1-like proteases (Ge and Greenspan, 2006). This results in the 
release of mature TGF-β, which in turn binds to a heterotetrameric receptor consisting of two 
type I and two type II serine/threonine kinase molecules (TGFBRI and II) (Wrana et al., 1992). Their 
activation results in the downstream phosphorylation of the signal transducers SMAD2 and SMAD3 
and their association with SMAD4. The active SMAD complex accumulates in the nucleus where it 
regulates transcription of several target genes including connective tissue growth factor (CTGF) and 
plasminogen activator inhibitor-1 (PAI-1) (Chen et al., 2000, Laiho et al., 1986, Shi and Massague, 
2003). Of note, the extent and duration of signaling is accurately controlled at different steps 
during the pathway, including synthesis and activation of latent TGF-β, activation and stability of its 
receptors and other downstream signaling members (Moustakas and Heldin, 2009).  
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Figure 1.6: TGF-β signaling pathway. Schematic representation of transforming growth factor beta (TGF-β) synthesis, 
secretion, matrix deposition and signal transduction. See text for details. LAP: latency associated peptide; mat. TGF-β: 
mature form of TGF-β; LTBP-1: latent TGF-β binding protein; Type I, Type II: type I and type II serine/threonine kinase 
receptors; P: phosphate; SLC: small latency complex; LLC: large latency complex; CTGF: connective tissue growth factor; 
PAI-1: plasminogen activator inhibitor-1. 
 
Aberrant TGF-β signaling has been linked to several diseases, such as cancer, autoimmune diseases 
as well as vascular fibrosis. Moreover, TGF-β participates in disease mechanisms of cardiovascular 
disorders including hypertension, restenosis, heart failure and atherosclerosis (Ruiz-Ortega et al., 
2007). In addition, over the last decades several familial vascular diseases could be linked to TGF-β 
pathway members in agreement with the key role of TGF-β in blood-vessel morphogenesis and 
stability (ten Dijke and Arthur, 2007). For instance, TGF-β signaling was found to be enhanced in 
Marfan syndrome (MFS), a connective tissue disease characterized by aortic root aneurysms and 
dissections, caused by mutations in FBN1, which encodes the ECM component fibrillin-1 (Dietz et 
al., 1991). Investigation of MFS mouse models such as Fbn1C1039G demonstrated that fibrillin-1 
mutations lead to an altered matrix sequestration of the latent LTBP-1/TGF-β complex resulting in 
an uncontrolled and increased TGF-β activity (Habashi et al., 2006, Neptune et al., 2003). 
Administration of TGF-β neutralizing antibodies to these mice prevented aortic aneurysms further 
demonstrating a role of enhanced TGF-β signaling in the disease pathomechanism (Habashi et al., 
2006).  
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1.4.2 Role in CARASIL 
Following the identification of HTRA1 as the gene defective in CARASIL evidence has accumulated 
supporting a specific role of the TGF-β signaling pathway in the disease pathogenesis. First, 
increased expression levels of LAP, TGF-β, phosphoSMAD2 and the TGF-β target genes hyaluronan 
and fibronectin (extra domain-A), were observed in cerebral arteries of two CARASIL patients 
(A252T, R302X) using in situ hybridization or immunohistochemistry (Figure 1.7) (Hara et al., 2009, 
Shiga et al., 2011). Second, expression levels of the TGF-β target gene noggin were found to be 
elevated in patient skin fibroblasts (Hara et al., 2009). Third, non-vascular symptoms often 
observed in CARASIL patients (alopecia, spondylosis) are compatible with dysregulation of TGF-β 
family member activity in the skin and skeletal system (Botchkarev, 2003, Yoon and Lyons, 2004). In 
agreement with this, HtrA1-deficient mice displayed elevated trabecular bone mass (Graham et al., 
2013). Moreover, TGF-β target genes known to stimulate bone formation were increased after 
TGF-β induction in HtrA1-deficient embryonic fibroblasts (Graham et al., 2013). Fourth, CARASIL 
mutations were shown to prevent HtrA1-mediated TGF-β inhibition in a luciferase reporter assay 
(Hara et al., 2009, Nishimoto et al., 2011) and in fibroblasts from a CARASIL patient carrying the 
R370X mutation (Shiga et al., 2011). This could be abolished upon restoration of HtrA1 expression 
(Hara et al., 2009, Shiga et al., 2011). 
 
 
Figure 1.7: Increased TGF-β signaling in cerebral small arteries of a CARASIL patient. (A, B) phosphoSMAD2 staining; (C, 
D) LAP staining; (A, C) control subject; (B, D) CARASIL (R302X). (B) Increased phosphoSMAD2 immunoreactivity in 
endothelial cells of a CARASIL patient. Arrowheads indicate nuclei with positive phosphoSMAD2 staining. (D) Increased 
LAP expression in CARASIL arterial walls. No immunoreactivities were detected in controls (A, C). Adapted from Shiga et 
al. (2011). 
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Deregulated TGF-β signaling has also been implicated in sporadic SVD (Thompson and Hakim, 
2009). It was reported to be up-regulated in ischemia (Doyle et al., 2010, Klempt et al., 1992) and 
chronic overproduction of TGF-β might induce microvascular degeneration (Wyss-Coray et al., 
2000). Furthermore, TGF-β plays a key role in tissue fibrosis by stimulating expression of ECM 
components including collagen in myofibroblasts, resulting in ECM overproduction (Ihn, 2002). In 
addition, TGF-β plays an important role in vasculogenesis, angiogenesis and blood vessel stability 
(ten Dijke and Arthur, 2007).  
The precise molecular mechanisms how HtrA1 interferes with TGF-β signaling have not been fully 
elucidated. Oka et al. (2004) reported that HtrA1 is co-expressed with TGF-β during embryonic 
development in mice and demonstrated an interaction between HtrA1 and various TGF-β 
superfamily members such as TGF-β, bone morphogenetic protein (BMP) 2 and 4, growth 
differentiation factor (GDF) 5 and 6 and activin, using a GST-pulldown assay (Oka et al., 2004). The 
authors could also show in luciferase assays and a developmental chick eye model system that 
HtrA1 inhibits signaling by TGF-β family members. In 2008, Launay et al. reported the degradation 
of recombinant mature TGF-β1 by HtrA1 in vitro. However, Shiga et al. (2011) suggested an 
alternative mechanism by providing evidence for HtrA1-mediated intracellular cleavage of the 
latency-associated peptide (LAP) of proTGF-β within the endoplasmic reticulum (ER). Most 
recently, cleavage of proTGF-β receptors (TGFBRII and TGFBRIII) by HtrA1 was reported (Graham et 
al., 2013). Irrespective of the mechanism all studies proposed an attenuation of TGF-β signaling by 
HtrA1 and an increased activity in CARASIL-affected tissues. 
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1.5 Scope of the thesis 
Despite the identification of HTRA1 as the CARASIL-causing gene the molecular events underlying 
disease pathogenesis are incompletely understood. An enhancement of TGF-β signaling activity 
resulting from the lack of HtrA1-mediated proteolytic processing of TGF-β pathway components 
has been proposed as a crucial step, but none of the proposed substrates (mature TGF-β, 
pro-TGF-β, type II and type II TGF-β receptors) has undergone a rigorous analysis including e.g. 
demonstration of processing by endogenous HtrA1. We therefore set out to investigate the 
consequences of a loss of HtrA1 function in mice as well as human cells by addressing the following 
questions:  
- Is CARASIL pathology recapitulated in HtrA1 knockout mice? 
Embryonic stem cells carrying an interrupted HTRA1 allele generated by gene trapping had 
been produced. These cells were intended to be used for the generation of homozygous 
HtrA1 knockout mice. The analysis plan of these mice included a basic characterization 
involving embryonic lethality and life expectancy as well as the examination of 
extraneurological (alopecia, spondylosis) and neurological CARASIL symptoms (white 
matter changes, smooth muscle cell degeneration). 
- What are the consequences of HtrA1 deficiency on TGF-β signaling?  
To address this question, we aimed to design several assays suited for analyzing TGF-β 
signaling activity in young and aged HtrA1-deficient mice. To analyze effects on a cellular 
level we sought to generate HtrA1-deficient mouse embryonic fibroblast lines as well as 
primary skin fibroblasts from CARASIL patients. 
- Which HtrA1 substrate might mediate possible effects on the TGF-β pathway? 
To identify physiologically relevant HtrA1 substrates, in vitro assays were to be developed 
to investigate the proteolysis of established (mature TGF-β, pro-TGF-β) and newly 
identified (latent TGF-β binding protein 1, LTBP-1) substrates in detail. In addition, we 
aimed to demonstrate substrate processing by endogenous HtrA1 using conditioned 
supernatants of embryonic fibroblasts.  
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2 Materials and methods 
2.1  Equipment 
15 ml falcons VWR 
24-well cell culture dishes BD Falcon 
50 ml falcons BD Falcon 
6-well cell culture dishes Omnilab 
96-well microplates PS, F-bottom Greiner bio-one 
Autoclave VX 150, DX 65 Systec 
Biosphere filtertips, extralong (200 µl; 1250 µl) Sarstedt 
Canulas No. 14 BD Microlance™ 3, 23G  BD Medical 
Canulas No. 18 BD Microlance™ 3, 25G BD Medical 
Cell scrapers BD Bioscience 
Cell strainers, 40 µm BD Falcon 
Centrifuge Avanti J-26 XP with swinging rotor JS 7.5 Beckmann Coulter 
Clean bench HeraSafe KS18 Heraeus 
CO2 incubator HeraCell Heraeus 
Cooling centrifuge Heraeus Megafuge 16R Thermo Scientific 
Centrifuge 5417R, 5415D Eppendorf 
Coverslides 22x50 mm #1 Menzel Glas 
Disposable cryotubes, 1.8 ml Nunc 
Filtertips 10 µl E long Peqlab 
Filtertips 10 µl G short Peqlab 
Forceps, scissors F.S.T. 
Freezer -80  C Hera Freeze Top Thermo Scientific 
Incubation shaking cabinet Certomat BS-1 Sartorius 
Liquid nitrogen tank Cryoplus 2 Thermo Scientific 
Magnetic stirrer KMO 2 basic IKA 
Microscope Axiovert 200M; camera AxioCam MRm Zeiss 
Microscope slides superfrost Plus Menzel Glas 
Microscope Wilovert S Hund Wetzlar 
Microwave Siemens 
Needles with cannula (0,33x12 mm, Myjector U40) Terumo 
PCR machine PTC-200 MJ Reserach 
pH-electrode Schott Instruments 
pH-meter Lab 850 Schott Instruments 
Pipettor Pipetboy Integra 
Power Supply Power Pac 200 Bio-Rad 
Power Supply Power Pac 300 Bio-Rad 
Power Supply Power Pac HC Bio-Rad 
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Protein LoBind tubes 1.5 ml Eppendorf 
Rocking shaker ST5 CAT Neolab 
Safe lock tubes (0.5 ml; 1.5 ml; 2.0 ml) Eppendorf 
SafeGuard filtertips (20 µl; 200 µl; 1000 µl) Peqlab 
Scale CS Series, 200 g Ohaus 
Shaker ST 5 CAT Neolab 
Sterile disposable pipettes (2 ml; 5 ml; 10 ml; 25 ml) Sarstedt 
Syringe BD Discardit™ II (5 ml; 10 ml) BD Biosciences 
Syringe Inject®-F Luer Duo (1 ml) B. Braun 
Thermo shaker Thriller Peqlab 
TipOne tips (10 µl; 200 µl; 1000 µl) StarLab 
Tissue culture flasks T25 Corning 
Tissue culture flasks T80 Nunc 
Tissue grinder, Type Potter-Elvehjem, smooth pestle Wheaton 
Vortex genie 2 Scientific Industries 
Water bath 1005 GFL 
Water purification system Mili-Q (Q-POD) Milipore 
  
2.2  Chemicals 
2-Mercaptoethanol (β-ME) ≥ 99,0 % Sigma 
Acetone Merck 
Acrylamide (Ultra Pure Proto Gel 30 %) National diagnostics 
Agar Invitrogen 
Agarose peqGOLD Universal Peqlab 
Aluminium sulfate hydrate Sigma 
Ammonium persulfate (APS) Sigma 
Ampicillin Sigma 
Boric acid (H3BO3) Sigma 
Bovine serum albumin (BSA) Sigma 
Bromophenol blue Sigma 
Coomassie brilliant blue G250 Fluka 
Cresyl violet acetate Sigma 
Dimethyl sulfoxide (DMSO) Sigma 
Disodium phosphate (Na2HPO4) Merck 
Dithiothreitol (DTT) Sigma 
Ethanol 70 % Roth 
Ethanol 96 % Roth 
Ethanol absolute, for analysis Merck 
Ethylenediaminetetraacetic acid (EDTA) Roth 
Eukitt®  Fluka 
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Glycerol ≥ 99.5 % Roth 
Glycine Sigma 
Heparin-Natrium-5000 Ratiopharm 
HEPES Roth 
Hydrogen chloride (HCl) Roth 
Ketamine hydrochloride Ketavet® 100 mg/ml Pfizer 
Lithium carbonate (Li2CO3) Roth 
Luxol® fast blue Merck 
Methanol ≥99 % Roth 
Monopotassium phosphate (KH2PO4) Merck 
NP-40 Fluka 
Orange G Sigma 
Paraformaldehyde (PFA) 4 % in PBS 7.4 Morphisto 
Peptone from casein Serva 
Phosphoric acid Sigma 
Protease inhibitor (cOmplete, Mini, EDTA-free cocktail tablets) Roche 
Select agar Invitrogen 
Skim milk powder Fluka 
Sodium bicarbonate (NaHCO3) Sigma 
Sodium chloride (NaCl) Roth 
Sodium chloride (NaCl) 0.9 % B. Braun 
Sodium deoxycholate Sigma 
Sodium dodecyl sulphate (SDS) Pellets Serva 
Sodium fluoride (NaF) Sigma 
Sodium hydroxide (NaOH) Roth 
Sodium orthovanadate (Na2VO4) Sigma 
Tetramethylethylenediamine (TEMED) Roth 
Tris(hydroxymethyl)aminomethane (Tris) HCl Roth 
Tris, Trizma® base Sigma 
Triton X-100 Sigma 
Tween-20 Roth 
Xylazin 2 % Albrecht 
Xylene cyanole ICN 
Yeast extract Roth 
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2.3  DNA techniques 
2.3.1  Plasmids 
Plasmids used in this thesis are listed in Table 2.1. Details about those plasmids that were 
generated in this thesis are shown in Table 2.2. 
Table 2.1: List of plasmids. Sources: (1) Invitrogen; (2) this thesis, for details see Table 2.2.; (3) N. Beaufort, ISD, Munich, 
Germany. 
Name Description Source 
pcDNA4_TOA mammalian expression vector (1) 
pcDNA4_TOA-hHtrA1mycHIS encodes human HtrA1 WT fused to a C-terminal 
myc/HIS tag 
(2) 
pcDNA4_TOA-hHtrA1-S328AmycHIS contains the mutation S238A in hHtrA1 (2) 
pcDNA4_TOA-hHtrA1-A252TmycHIS contains the mutation A252T in hHtrA1 (2) 
pcDNA4_TOA-hHtrA1-G295RmycHIS contains the mutation G295R in hHtrA1 (2) 
pcDNA4_TOA-hHtrA1-V297MmycHIS contains the mutation V297M in hHtrA1 (2) 
pcDNA4_TOA-mHtrA1mycHIS encodes mouse HtrA1 WT fused to a myc/HIS tag (2) 
pcDNA4_TOA-mHtrA3mycHIS encodes mouse HtrA3 WT fused to a myc/HIS tag (2) 
pcDNA4_TOA-mHtrA4mycHIS encodes mouse HtrA4 WT fused to a myc/HIS tag (2) 
pcDNA3-LTBP1S_FL encodes human LTBP-1S (Jorma Keski-Oja, Helsinki, 
Finland) fused to a CD5 signal peptide, an N-terminal 
HA-tag and a C-terminal V5/HIS tag 
(3) 
ptt5-LTBP1S_ΔC encodes C-terminally truncated human LTBP-1S (aa 
1-689) fused to a C-terminal V5/HIS tag 
(3) 
pTT5-TGF-β1_V5 encodes human TGF-β1 fused to a C-terminal V5/HIS 
tag 
(3) 
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Table 2.2: Plasmids generated during this thesis. Primers (see Table 2.3), templates, and restriction sites used for cloning 
are listed. For construct generation methods see chapter 2.3.5-2.3.12. Generation: (P,OL,D,L) standard PCR, overlapping 
PCR, digestion of the backbone vector and the PCR product, ligation; (P,D,L) standard PCR, digestion of the backbone 
vector and the PCR product, ligation; (SM) site-directed mutagenesis. 
 
2.3.2 Oligonucleotides 
If not stated otherwise, oligonucleotides were designed with CLC DNA Workbench and 
manufactured by Metabion, Martinsried, Germany. 
Table 2.3: List of oligonucleotides. 
Name Sequence Application 
hHtrA1-RXhoI-o.Stp 5´-GCCTCGAGTGGGTCAATTTCTTCGGGA -3´ cloning 
hHtrA1-FEco 5’-GAGAATTCGTCGCCATGCAGATCCC-3’ cloning 
F402mHtrA3 5´-GCCTCGAGTTCGGGCCTCGGTATC-3´ cloning 
   
Name Primers Template Restriction 
enzymes 
Genera-
tion 
pcDNA4_TOA-hHtrA1 hHtrA1-FBam, 
hHtrA1-R845; 
hHtrA1-F845, 
hHtrA1-Reco 
pBSR-hHtrA1 (imaGenes), 
pcDNA4_TOA 
BstEII, XhoI (P,OL,D,L) 
pcDNA4_TOA-
hHtrA1mycHIS 
hHtrA1-FEco, hHtrA1-
RXhoI-o.Stp 
pcDNA4_TOA-hHtrA1, 
pcDNA4_TOA 
EcoRI, XhoI (P,D,L) 
pcDNA4_TOA-hHtrA1-
S328AmycHIS 
hHtrA1-S328A_F, 
hHtrA1-S328A_R 
pcDNA4_TOA-hHtrA1mycHIS - (SM) 
pcDNA4_TOA-hHtrA1-
A252TmycHIS 
hHtrA1-A252T_F, 
hHtrA1-A252T_R 
pcDNA4_TOA-hHtrA1mycHIS - (SM) 
pcDNA4_TOA-hHtrA1-
G295RmycHIS 
hHtrA1-G295R_F, 
hHtrA1-G295R_R 
pcDNA4_TOA-hHtrA1mycHIS - (SM) 
pcDNA4_TOA-hHtrA1-
V297MmycHIS 
hHtrA1-V297M_F, 
hHtrA1-V297M_R 
pcDNA4_TOA-hHtrA1mycHIS - (SM) 
pcDNA4_TOA-
mHtrA1mycHIS 
mHtrA1-FEco, 
mHtrA1-XbaI-o.Stp 
pCMV SPORT6 mHtrA1 
(Source BioScience), 
pcDNA4_TOA-hHtrA1mycHIS 
EcoRI, XbaI (P,D,L) 
pcDNA4_TOA-
mHtrA3mycHIS 
F402mHtrA3, 
R1814mHtrA3 
pCR4-TOPO-mHtrA3 
(imaGenes), pcDNA4_TOA 
XbaI, XhoI (P,D,L) 
pcDNA4_TOA-
mHtrA4mycHIS 
F89mHtrA4, 
R1537mHtrA4 
pCR4-TOPO-mHtrA4 
(imaGenes), pcDNA4_TOA 
XbaI, XhoI (P,D,L) 
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Name Sequence Application 
R1814mHtrA3 5´-GCTCTAGACATGACCACCTCAGGGA-3´ cloning 
F89mHtrA4 5´-GCCTCGAGGCCGCCATGAGCTTCCAGCGGT-3´ cloning 
R1537mHtrA4 5´-GCTCTAGAATTGATTATTTCAGGTGTGAC-3´ cloning 
hHtrA1-FBam 5´-GAGGATCCGTCGCCATGCAGATCCCG-3´ cloning 
hHtrA1-F845 5´-CCAAAATCAAGGATGTGGATGAGAAAGCAGACATC-3´ cloning 
hHtrA1-R845 5´-GATGTCTGCTTTCTCATCCACATCCTTGATTTTGG-3 cloning 
hHtrA1-REco 5´-GCGAATTCCTATGGGTCAATTTCTTCGG-3´ cloning 
mHtrA1-FEco 5´-GAGAATTCTCGGAGTCGTCATGCAGT-3´ cloning 
mHtrA1-XbaI-o.Stp 5´-GCTCTAGAGTAGGGGTCGATTTCTTCAGG-3´ cloning 
TF1102-5´ 5´-AGGGTCTCAAGTATCCAGGTTG-3´ genotyping 
TF1102-3´ 5´-CCAGAAATAAGACTCGGACTCA-3´ genotyping 
LTR-rev 5´-ATAAACCCTCTTGCAGTTGCATC-3´ genotyping 
mHtrA1OKA3_F 5´-CAGCTGCCACCGTCTGTC-3´ genotyping 
mHtrA1OKA3_R 5´-GGCACAGGTTGGTGTAGGTC-3´ genotyping 
Oka Neo for 5´-CTTGGGTGGAGAGGCTATTC-3´ genotyping 
Oka Neo rev 5´-AGGTGAGATGACAGGAGATC-3´ genotyping 
F358-mouse 5´-GGTAGCGACGCCAAGACCTACACCA-3´ HtrA1 mRNA analysis 
F471-mouse 5´-AGGGCAGGAAGATCCCAA-3´ HtrA1 mRNA analysis 
R764-mouse 5´-TTCCCTGGTGGTCAATCT-3´ HtrA1 mRNA analysis 
R1005-mouse 5´-GTTAATCCCAATCACCTCGCCATCC-3´ HtrA1 mRNA analysis 
rt-mHtrA1_F 5´-GGCGAGGTGATTGGGATTAA-3´ HtrA1 mRNA 
analysis/real-time PCR 
rt-mHtrA1_R 5´-TCCGTTGATGCTGATGATG-3´ HtrA1 mRNA 
analysis/real-time PCR 
qRT_m_ACTA2_f 5´-CCAGCACCATGAAGATCAAG-3´ real-time PCR 
qRT_m_ACTA2_r 5´-CTTCGTCGTATTCCTGTTTGC-3´ real-time PCR 
mActinb_#63_F 5´-GGATGCAGAAGGAGATTACTGC-3´ real-time PCR 
mActinb_#63_R 5´-CCACCGATCCACACAGAGTA-3´ real-time PCR 
mCTGF#71-F 5´-TGACCTGGAGGAAAACATTAAGA-3´ real-time PCR 
mCTGF#71-R 5´-AGCCCTGTATGTCTTCACACTG-3´ real-time PCR 
mHtrA3_#22_F 5´-AAGCGCTTCATTGGCATC-3´ real-time PCR 
mHtrA3_#22_R 5´-TGCTGACCGCTGGAAAGT-3´ real-time PCR 
mHtrA4_#66_F 5´-TCCCTGATGTGAGTTCTGGA-3´ real-time PCR 
mHtrA4_#66_R 5´-CAATTACATCATGGTCTCTCAACC-3´ real-time PCR 
mPAI-1_#80_F 5´-CCTCCTCATCCTGCCTAAGTT-3´ real-time PCR 
mPAI-1_#80_R 5´-GGCCAGGGTTGCACTAAAC-3´ real-time PCR 
h_bActin_qRT_f 5´-AGAGCTACGAGCTGCCTGAC-3´ real-time PCR 
h_bActin_qRT_r 5´-CGTGGATGCCACAGGACT-3´ real-time PCR 
hCTGF_#71_F 5´-AGCTGACCTGGAAGAGAACATT-3´ real-time PCR 
hCTGF_#71_R 5´-GCTCGGTATGTCTTCATGCTG-3´ real-time PCR 
hPAI-1_2_F 5´-CTCCTGGTTCTGCCCAAGTT-3´ real-time PCR 
hPAI-1_2_R 5´-GAGAGGCTCTTGGTCTGAAAG-3´ real-time PCR 
Oligo dT (15) 5´-TTTTTTTTTTTTTTT-3´ cDNA synthesis 
Materials and methods 
20 
2.3.3 RNA isolation and cDNA synthesis 
Up to 25 mg mouse tissue was homogenized in a TissueLyser LT (Qiagen) with a 5 mm metal-ball 
(Qiagen) for 3 min at 50 hertz in 350 µl (aorta, isolated brain vessels) or 600 µl (brain, heart, kidney, 
lung) RLT buffer (Qiagen) with 40 mM DTT. After centrifugation for 3 min at 16300 g, total RNA was 
isolated from the supernatant using the RNeasy Mini kit (Qiagen) according to the manufacturer’s 
protocol. Total RNA from MEF cells was isolated using 350 µl RLT buffer (Qiagen) with 40 mM DTT 
without preceding homogenization using the RNeasy Mini kit (Qiagen). For genomic DNA removal 
the RNase-Free DNase Set (Qiagen) was used during RNA purification according to the 
manufacturer’s specifications. The concentration and quality of RNA was checked using the 
Nanodrop ND-1000 (Peqlab) or the Qubit 2.0 Fluorometer (Life Technologies) and loading each 
RNA sample on an electrophoresis gel. 250-1000 ng of RNA (brain, heart, kidney, lung, MEF cells) or 
13.2 µl of eluted RNA (aorta, isolated brain vessels) in a total volume of 20 µl were used for the 
cDNA synthesis using the primer Oligo dT (15) (see Table 2.3) and the Omniscript RT kit (Qiagen). 
 
2.3.4  Quantitative real-time PCR 
For real-time PCR reactions 1.25 % (brain, heart, kidney, lung, MEF cells) or 6.25 % (aorta, isolated 
brain vessels) of the cDNA were mixed with Brilliant II SYBR Green QPCR Master Mix (Agilent 
Technologies). Primers were designed with the CLC DNA Workbench or primer sequences were 
acquired from Roche Universal Probe Library to amplify regions of mRNA transcripts between 80-
150 bp in length (see Table 2.3). To minimize interference caused by contaminant genomic DNA, 
primer pairs were separated by intron sequences of at least 1000 bp. PCR reactions were run on 
the Stratagene Mx3000P real-time PCR system (Agilent Technologies) and analyzed with MxPro 
QPCR Software (Agilent Technologies). Melting curves made at the end of every run confirmed the 
presence or deficiency of PCR products. Samples were run in duplicates or triplicates and 
expression levels, normalized to β-Actin or GAPDH, were determined by the comparative CT 
method (Livak and Schmittgen, 2001). 
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Table 2.4: Real-time PCR program. 
Step Temperature Period 
Denaturation 95 °C 10 min 
40 cycles:   
Denaturation 95 °C 30 s 
Annealing 60 °C 1 min 
Elongation 72 °C 1 min 
Melting curve:   
 55-95 °C continuously 
 
2.3.5 PCR 
Standard PCR was performed to amplify a certain DNA sequence with DNA polymerase and buffers 
purchased from Life Technologies. 
 
Table 2.5: PCR reaction mix. 
Component  Volume 
2 U/µl AccuPrime DNA Polymerase 0.5 µl 
5x AccuPrime Buffer B 5 µl 
Template 30 ng 
Forward primer (10 µM) 0.5 µl 
Reverse primer (10 µM) 0.5 µl 
H2ODI ad 25 µl 
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Reaction was performed in a thermocycler using the following program: 
Table 2.6: PCR program. 
Step Temperature Period 
Denaturation 95 °C 3 min 
30 cycles:   
Denaturation 95 °C 30 s  
Annealing 50-60 °C 30 s 
Elongation 72 °C 1 min / kb 
Elongation 72 °C 10 min 
Storage 4 °C infinite 
 
PCR products were purified using the QIAquick PCR Purification kit (Qiagen) according to the 
manufacturer’s specifications. 
 
2.3.6  Site-directed mutagenesis 
Oligonucleotides for site-directed mutagenesis were designed with the help of the QuikChange 
Primer Design Program (Agilent Technologies). Mutations were inserted using the QuikChange 
Lightning Site-Directed Mutagenesis kit (Agilent Technologies) according to the manufacturer’s 
protocol.  
 
2.3.7  Agarose gel electrophoresis 
TBE buffer: 
89 mM Boric acid, 2 mM EDTA, 89 mM Trizma® base, pH 8.0  
 
DNA loading buffer (6x): 
60 % glycerol, 60 mM EDTA, 0.025 % (w/v) Xylene Cyanol, 0.025 % (w/v) Orange G, 10 mM Trizma® Hydrochloride, pH 7.6 
Gel electrophoresis was applied for the analytical and preparative separation of DNA and RNA. 
Depending on fragment size, 0.7 - 2 % (w/v) agarose was dissolved in TBE buffer, heated in the 
microwave and 1:10000 SYBR® Safe DNA Gel stain (Life Technologies) was added. DNA- or 
RNA-samples were mixed with 1x DNA loading buffer and electrophoresis was performed in TBE 
buffer using PerfectBlue gelsystems (Peqlab) with a constant voltage of 80 volt (small chambers) or 
100 volt (large chambers) for 1 h. As a molecular marker peqGOLD 50 bp DNA ladder (Peqlab, 50-
1000 bp) or peqGOLD DNA ladder mix (Peqlab, 100-10000 bp) was used. The fluorescence signal 
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was detected with the Fusion FX7 (Vilber Lourmat). An alternative system to analyze PCR fragments 
was applied using the QIAxcel Advanced System (Qiagen) and the QIAxcel DNA Screening Gel 
Cartridge (Qiagen) according to the manufacturer’s specifications. 
 
2.3.8  Restriction enzyme treatment 
Analytical or preparative DNA restriction was carried out with restriction enzymes and buffers 
purchased from NEB (see Table 2.2). The type of buffer and the temperature of incubation were 
recommended by the manufacturer. The amount of enzyme was calculated depending on the 
amount of DNA. Restriction fragments obtained were analyzed and purified by DNA extraction 
using the GeneJET Gel Extraction kit (Fermentas) according to the manufacturer’s specifications. 
 
Table 2.7: Restriction enzyme treatment. 
Component  Volume 
Restriction enzyme 1 10 U 
Restriction enzyme 2 (optional) 10 U 
Restriction buffer 3 µl 
DNA 500 ng (preparative digestion) 
1000 ng (analytical digestion) 
10x BSA (optional) 3 µl 
H2ODI ad 30 µl 
 
2.3.9 Vector dephosphorylation 
To avoid religation of linearized plasmids with compatible ends, 5´ phosphate groups from 
restricted DNA were removed by adding Antarctic Phosphatase (NEB) to the restricted DNA (see 
chapter 2.3.8) according to the manufacturer’s protocol. 
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2.3.10 DNA ligation 
Ligation was performed adding 1 µl T4 DNA Ligase (NEB), 2 µl ligase buffer (NEB) and H2ODI up to a 
volume of 20 µl to the DNA. Restricted plasmid DNA and the DNA fragment were ligated in a molar 
ratio of 1:3 for 1 h at room temperature. 
 
2.3.11 Transformation of competent bacteria 
Luria-Bertani broth (LB medium): 
1 % (w/v) peptone, 0.5 % (w/v) NaCl, 0.5 % (w/v) yeast extract, pH 7.0, autoclaved 
 
LBamp medium: 
LB medium; after cooling the autoclaved medium to about 50 °C, 100 µg/ml ampicillin was added. 
 
LBamp agar plates: 
LB medium, 1.5 % (w/v) agar; after cooling the autoclaved medium to about 50 °C, 100 µg/ml ampicillin was added. 
 
50 µl of competent E. coli DH5α cells were mixed with 100 ng DNA or 2 µl ligation mix and 
incubated for 30 min on ice. Then cells were heated for 90 s at 42 °C and subsequently cooled on 
ice for 5 min. 200 µl LB medium was added to the cell suspension followed by incubation at 37 °C 
for 1 h. 100 μl of the outgrowth was spread on LBamp agar plates. After incubation overnight at 37 
°C, colonies were picked and further incubated overnight at 37 °C in 4 ml or 100 ml LBamp medium 
under gentle shaking. 
 
2.3.12 DNA isolation from bacteria 
Isolation of plasmid-DNA was carried out using commercially available anion-exchange columns. 
For small amounts of plasmid-DNA (4 ml LB medium), the NucleoSpin Plasmid kit (Macherey-Nagel) 
was used according to the manufacturer´s instructions. DNA was eluted in 30 µl elution buffer. For 
plasmid-DNA isolation from 100 ml overnight cultures, the NucleoBond Xtra Midi kit (Macherey-
Nagel) was used according to the manufacturer´s instructions. DNA was eluted in 500 µl elution 
buffer. The concentration and quality of DNA was checked using the Nanodrop ND-1000 (Peqlab). 
Before the plasmid was sent for sequencing to GATC Biotech AG (Konstanz, Germany), analytical 
restriction analysis was carried out to ensure the correct build-up of the plasmid (see chapter 
2.3.8). 
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2.4 Mouse techniques 
2.4.1  Strains 
 
Table 2.8: Mouse strains used in this thesis. 
Strain name Nomenclature Gene Mutation Source / 
Reference 
HtrA1
-/-
(gt) HtrA1
Gt(OST394864)Lex 
HtrA1; location: 
Chr7:130936111-130985660 
bp, + strand; genetic 
position: Chr7, 73.2 cM 
Gene trap 
OST394864 
Lexicon 
Genetics; 
Taconic  
HtrA1
-/-
(tm) HtrA1
tm1Ybf
 HtrA1; location: 
Chr7:130936111-130985660 
bp, + strand; genetic 
position: Chr7, 73.2 cM 
Targeted 
mutation: 
insertion, 
intragenic 
deletion 
Yingbin Fu (Jones 
et al., 2011) 
 
2.4.2 Isolation of genomic DNA from mouse tissue 
Isolation of genomic DNA was performed by incubation of mouse tail biopsies or ear mark tissue 
with 50 mM NaOH at 97 °C for 30 min. Samples were neutralized with 30 µl 1M Trizma® 
hydrochloride, pH 7.0. 
 
2.4.3  PCR genotyping 
For PCR genotype analysis of the two mouse strains the respective primers were used (see Table 
2.3). Sequences of oligonucleotides were either recommended by Taconic (HtrA1(gt) strain) or 
designed with the CLC DNA Workbench (HtrA1(tm) strain). The PCR products represented either 
the wild-type HtrA1 locus (HtrA1(gt) strain: 434 bp; HtrA1(tm) strain: 297 bp) or the mutant locus 
(HtrA1(gt) strain: 281 bp; HtrA1(tm) strain: 280 bp). The respective PCRs were performed with DNA 
polymerase and buffers purchased from Fermentas using the following components and the 
following programs (see Table 2.9 for the HtrA1(gt) mouse PCR and Tables 2.10 and 2.11 for the 
HtrA1(tm) mouse PCR). 
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Table 2.9: PCR reaction mix and program for the combined detection of the wild-type and mutant locus of HtrA1(gt) 
mice. 
Component  Volume  Step Temperature Period 
5 U/µl Taq DNA polymerase  0.5 µl  Denaturation 95 °C 10 min 
10X Taq Buffer with KCl 5 µl  30 cycles:   
25 mM MgCl2 6.5 µl  Denaturation 95 °C 2 min  
10 mM dNTPs 1 µl  Annealing 65 °C 1 min 
Tissue lysate 3 µl  Elongation 72 °C 30 s 
TF1102-3´ 1 µl  Elongation 72 °C 10 min 
TF1102-5´ 1 µl  Storage 4 °C infinite 
LTR-rev 1 µl     
H2ODI 31 µl     
 
Table 2.10: PCR reaction mix and program for the detection of the wild-type locus of HtrA1(tm) mice. 
Component  Volume  Step Temperature Period 
5 U/µl Taq DNA polymerase 0.5 µl  Denaturation 95 °C 10 min 
10X Taq Buffer with KCl 5 µl  35 cycles:   
DMSO 5 µl  Denaturation 95 °C 30 s 
25 mM MgCl2 3.5 µl  Annealing 60 °C 45 s 
10 mM dNTPs 1 µl  Elongation 72 °C 1 min 
Tissue lysate 3 µl  Elongation 72 °C 10 min 
mHtrA1OKA3_F 1 µl  Storage 4 °C infinite 
mHtrA1OKA3_R 1 µl     
H2ODI 30 µl     
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Table 2.11: PCR reaction mix and program for the detection of the mutant locus of HtrA1(tm) mice. 
Component  Volume  Step Temperature Period 
5 U/µl Taq DNA polymerase 0.5 µl  Denaturation 95 °C 10 min 
10X Taq Buffer with KCl 5 µl  35 cycles:   
5 x Q-Solution (Qiagen) 10 µl  Denaturation 95 °C 30 s 
25 mM MgCl2 3.5 µl  Annealing 58 °C 1 min 
10 mM dNTPs 1 µl  Elongation 72 °C 2 min 
Tissue lysate 3 µl  Elongation 72 °C 10 min 
Oka Neo for 1 µl  Storage 4 °C infinite 
Oka Neo rev 1 µl     
H2ODI 25 µl     
 
2.4.4 Isolation of mouse tissue 
Ketamine/Xylazine anaesthesia: 
0.6 ml Ketamine 10 %, 0.2ml Xylazine 2 %, 0.2 ml 0.9 % NaCl solution; injection per mouse: 0.3-0.4 ml (6-8 mg/kg Xylazine, 90-120 mg/kg 
Ketamine) 
 
PBS: 
154 mM NaCl, 9.5 mM Na2HPO4, 1.7 mM KH2PO4, pH 7.4 
 
Heparin perfusion: 
5 ml 25 units Heparin followed by 5 ml 12.5 units Heparin and 10 ml PBS 
 
Mice were deeply anesthetized with Ketamine/Xylazine and perfused transcardially with either 
Heparin solutions (see above) or with 20-30 ml PBS. Lung, liver, kidney, heart, spleen, aorta and 
brain were harvested and immediately frozen on dry ice. All organs were stored at -80 °C. 
 
2.4.5  Isolation of mouse serum 
Mice were deeply anesthetized with Ketamine/Xylazine. Blood samples were collected from the 
right ventricle of the heart and were allowed to clot for 2 h at room temperature before being 
centrifuged for 20 min at 2000 g. Serum was removed and stored immediately at -80 °C.  
 
2.4.6 Isolation of mouse brain vessels 
Frozen mouse brain tissue was minced with a scalpel and homogenized in 15 ml cold Minimal 
Essential Media (MEM, Gibco®, Life Technologies) with 40-50 up-and-down strokes in a 
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Potter-Elvehjem tissue grinder. Equal volume of 30 % Ficoll® 400 (Sigma) in MEM was added and 
the suspension was centrifuged for 20 min at 6000 g and 4 °C. The supernatant was discarded and 
the pellet was resuspended in 1 % BSA in PBS. Then, the suspension was poured through a 40 µm 
nylon mesh and extensively washed with PBS. Microvessels were collected in PBS by inversion of 
the nylon mesh. The purity of the vessels was checked under the microscope and the suspension 
was centrifuged for 5 min at 3000 g and 4 °C. 
 
2.5 Cell culture 
2.5.1  Cell lines 
Table 2.12: Cell lines used in this thesis. Description: (1) Mouse embryonic fibroblasts derived from HtrA1
+/+
(gt) embryos 
(see chapter 2.4.1), immortalized through serial passaging; (2) Mouse embryonic fibroblasts derived from HtrA1
-/-
(gt) 
embryos (see chapter 2.4.1), immortalized through serial passaging. 
Cell line Description Source / Reference 
HEK293T Human embryonic kidney cells laboratory´s cell line collection 
MFB-F11 Mouse embryonic fibroblasts derived from 
TGF-β1
-/-
 embryos stably transfected with 
reporter plasmids consisting of TGF-β responsive 
SMAD-binding elements coupled to a secreted 
alkaline phosphatase reporter gene (pSBE-SEAP). 
(Tesseur et al., 2006) 
WT1(gt) (1) this study 
WT2(gt) (1) this study 
WT3(gt) (1) this study 
WT4(gt) (1) this study 
WT272(gt) (1) this study 
WT1o(gt) (1) this study 
WT2o(gt) (1) this study 
KO1(gt) (2) this study 
KO2(gt) (2) this study 
KO3(gt) (2) this study 
KO272(gt) (2) this study 
KO1o(gt) (2) this study 
KO2o(gt) (2) this study 
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Cell line Description Source / Reference 
WT(tm) Mouse embryonic fibroblasts derived from 
HtrA1
+/+
(tm) embryos (see chapter 2.4.1), 
immortalized through serial passaging during this 
thesis. 
kindly provided by M. Ehrmann, 
University Duisburg-Essen, 
Germany 
KO(tm) Mouse embryonic fibroblasts derived from 
HtrA1
-/-
(tm) embryos (see chapter 2.4.1), 
immortalized through serial passaging during this 
thesis. 
kindly provided by M. Ehrmann, 
University Duisburg-Essen, 
Germany 
WT/WT Human skin fibroblasts derived from a 45 year 
old male control 
kindly provided by D. Werring; 
UCL Institute of Neurology, 
National Hospital for Neurology 
and Neurosurgery, London, 
Great-Britain 
A321T/E42fs Human skin fibroblasts derived from a 29-year-
old Romanian female CARASIL patient carrying 
two heterozygous HTRA1 mutations: c.961G>A 
(aa substitution p.A321T) mutation in exon 4 and 
a G deletion c.126delG (frameshift p.E42fs; 
introduction of a stop codon at position 214) in 
exon 1; showed severe diffuse leukoencephalo-
pathy, subcortical infarcts, degenerative disc 
disease 
kindly provided by A. Federico, 
University of Siena, Italy 
(Bianchi et al., 2014) 
A173T/A173T Human skin fibroblasts derived from a 34-year-
old Pakistani female CARASIL patient carrying a 
homozygous HTRA1 mutation: c.517G>A (aa 
substitution p.A173T) mutation in exon 2; 
showed confluent T2 hyperintensities in 
periventricular, deep and subcortical cerebral 
WM and in the brainstem; multiple lesions in the 
corpus callosum and periventricular WM; 
arteriolosclerosis; minor non-compressive 
spondylosis 
kindly provided by D. Werring; 
UCL Institute of Neurology, 
National Hospital for Neurology 
and Neurosurgery, London, 
Great-Britain  
 
2.5.2 Mouse embryonic fibroblasts 
PBS (sterile): 
154 mM NaCl, 9.5 mM Na2HPO4, 1.7 mM KH2PO4, pH 7.4, autoclaved 
 
Medium: 
Dulbecco's Modified Eagle Medium (DMEM), high glucose, GlutaMAX™ Supplement (Gibco®, Life Technologies) 
 
Supplements: 
Fetal bovine serum (FBS) (Gibco®, Life Technologies) 
Penicillin/streptomycin (p/s) (100 U/ml penicillin, 100 µg/ml streptomycin) (Gibco®, Life Technologies) 
 
Mouse embryonic fibroblasts (MEF) were derived from 13.5-15.5 days post coitus embryos. 
Embryos were dissected from maternal tissue in sterile PBS followed by decapitation and removal 
of organs. The embryos were then placed in a petri dish with DMEM supplemented with 10 % FBS 
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and 2 % p/s and minced with a scissor. After incubation in a humidified 37 °C incubator containing 
5 % CO2 for 2 days, medium was changed and cells were grown to 80-90 % confluence. MEF cells 
were split every 3 days (see chapter 2.5.3) and a defined number of cells was seeded into T80 
flasks. Cells were immortalized through serial replating of the cells. During the rapid growth phase 
of the culture (the first 5-7 passages), cells were split twice a week 1:3 to 1:5. As the MEF cells 
entered crisis, cells were split 1:2 or merely replated. Starting at passage 10 immortalized cells 
began to overgrow the culture. Immortalized cells were split two or three times a week. 
 
2.5.3 Cell cultivation 
Medium: 
Dulbecco's Modified Eagle Medium (DMEM), high glucose, GlutaMAX™ Supplement (Gibco®, Life Technologies) 
 
Supplements: 
Fetal bovine serum (FBS) (Gibco®, Life Technologies) 
Penicillin/streptomycin (p/s) (100 U/ml penicillin, 100 µg/ml streptomycin) (Gibco®, Life Technologies) 
 
0.05 % Trypsin-EDTA 1x (Gibco®, Life Technologies) 
 
All cell lines were maintained in DMEM supplemented with 10 % FBS and 1 % p/s in a humidified 37 
°C incubator containing 5 % CO2. Cells were split at 80–90 % confluence (2-3 times a week). After 
washing with PBS, cells were trypsinized for 2 min at 37 °C. Detached cells were centrifuged for 5 
min at 400 g. Then, cell pellets were resuspended and an appropriate amount of cells were seeded 
in fresh medium. Cells were tested frequently for mycoplasma using the Venor GeM OneStep kit 
(Minerva Biolabs) or the MycoAlert™ PLUS Mycoplasma Detection kit (Lonza). 
 
2.5.4  Cell transfection 
Cells were counted using a TC20™ Automated Cell Counter (Bio-Rad) or a Neubauer chamber and a 
defined number was seeded into well plates. After overnight incubation, cells were washed with 
PBS and serum-free medium was added for 2 h. Transfection was performed with Lipofectamine® 
2000 (Life Technologies) or FuGENE® HD Transfection Reagent (Roche) according to the 
manufacturer´s manual. Following culturing for 24 h or 48 h in serum-free DMEM, medium was 
collected and centrifuged 10 min at 1000 g to eliminate cell debris. Cells were washed with PBS and 
collected in PBS followed by centrifugation for 10 min at 1000 g. 
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2.5.5  Cell cryoconservation 
Freezing medium: 
FBS containing 10 % DMSO 
 
For long term storage of cell lines, cells were trypsinized and pelleted (see chapter 2.5.3) and 
resuspended in freezing medium. The suspension was then transferred into a cryovial and allowed 
to slowly cool down overnight at -80 °C using a freeze-box (Mr. Frosty, Nalgene®). Finally, cryovials 
were transferred into a liquid nitrogen tank. If needed, cell suspensions were thawed by short 
incubation of the vial at 37 °C. After adding DMEM, cells were centrifuged and seeded with fresh 
medium into a new flask. 
 
2.5.6  Generation of cells and conditioned media from MEF cells 
Preparation of cells and conditioned medium for real-time PCR (chapter 2.3.4), total protein lysates 
(chapter 2.6.2), proteolysis assay (chapter 2.6.7), TGF-β ELISA (chapter 2.6.8) and active TGF-β 
measurement (chapter 2.6.9):  
Cells were counted using a TC20™ Automated Cell Counter (Bio-Rad) or a Neubauer chamber and a 
defined number was seeded into well plates. After overnight incubation, cells were washed with 
PBS and serum-free medium was added for 2 h. Following culturing for 24 h, 48 h or 72 h in fresh 
serum-free DMEM, medium was collected and centrifuged 10 min at 1000 g to eliminate cell 
debris. Media were directly analyzed or concentrated 10- to 20-fold by spinning 10 min at 4000 g 
and 4 °C using Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-3 membrane (Millipore). Cells 
were washed with PBS and collected in PBS followed by centrifugation for 10 min at 1000 g. 
 
Preparation of TGF-β1 stimulated MEF cells: 
Cells were counted and a defined number was seeded into well plates. After overnight incubation, 
cells were washed with PBS and serum-free medium was added for 10 h. Then, medium was 
exchanged to fresh serum-free DMEM with 1 or 10 ng/ml recombinant Human TGF-beta 1 (R&D 
Systems). Following culturing for 12 h, cells were washed with PBS and collected in PBS followed by 
centrifugation for 10 min at 1000 g. 
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2.6 Protein analysis methods 
2.6.1  Antibodies 
The monoclonal rat anti-HtrA1(16C8) antibody was generated in collaboration with Dr. Elisabeth 
Kremmer, HelmholtzZentrum, Munich, Germany. Rats were immunized with a synthetic HtrA1 
peptide corresponding to aa 155–170 of the human sequence and a C-terminal cysteine residue 
(CGQGQEDPNSLRHKYNC). Hybridoma cell supernatants were used undiluted for Western blotting. 
Table 2.13 and Table 2.14 list all primary and secondary antibodies that were used for Western 
blotting. 
 
Table 2.13: Primary antibodies used for Western blotting. 
Antibody Type Dilution Source 
β-Actin rabbit polyclonal 1:1000 SIGMA 
HtrA1(16C8) rat monoclonal pure E. Kremmer, 
HelmholtzZentrum, 
Munich, Germany 
HtrA1(ΔMac) rabbit polyclonal 1:1000 kindly provided by 
S. Fauser, 
University Cologne, 
Germany, 
(Vierkotten et al., 
2011) 
Myc(9E10) mouse monoclonal 1:5000 Hybridoma Bank, 
Iowa, USA 
Phospho-Smad2 (Ser465/467) 
(138D4) 
rabbit monoclonal 1:500 Cell Signaling 
α-Smooth Muscle Actin-Cy3™ mouse monoclonal 1:1000 SIGMA 
TGF-β1 rabbit polyclonal 1:2000 Torrey Pines 
Biolabs 
V5 mouse monoclonal 1:5000 Life Technologies 
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Table 2.14: Secondary antibodies used for Western blotting. 
Antibody Conjugate Dilution Source 
Goat anti-mouse HRP 1:10000 DAKO 
Goat anti-rabbit HRP 1:10000 DAKO 
Rabbit anti-goat HRP 1:10000 DAKO 
Rabbit anti-rat HRP 1:10000 DAKO 
 
2.6.2 Cell total protein lysates 
10x Protease inhibitor (PI): 
1 protease inhibitor tablet in 1 ml H2ODI  
 
SMAD lysis buffer: 
100 mM NaCl, 2mM EDTA, 50 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 0.1 % SDS, 0.5 % sodium deoxycholate, 1 % Triton-X 100, 10 % 
glycerol, 1 x PI, 10 mM Trizma® base, pH 7.6 
 
TNT lysis buffer: 
50 mM Tris-HCl, 200 mM NaCl, 0.5 % NP-40, 1x PI, pH 8.0 
 
Cells were washed with PBS and collected in PBS followed by centrifugation for 10 min at 1000 g. 
Pellet was lysed in SMAD lysis buffer for phosphoSMAD2 analysis or in TNT lysis buffer and 
incubated on ice for 20 min. Cell debris was removed by centrifugation for 10 min at 16300 g and 4 
°C. Total protein concentration of phosphoSMAD2 analysis lysates could not be determined 
because of incompatibilities of buffer components with available protein quantification assays. 
 
2.6.3 Mouse tissue protein lysates 
Tissue lysates: 
10x Protease inhibitor (PI): 
1 protease inhibitor tablet in 1 ml H2ODI  
 
Homogenisation Buffer: 
150 mM NaCl, 50 mM Trizma® base, pH 7.4; supplemented with 1 x PI, 50 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4 
 
10 x detergent: 
10 % NP-40, 5 % SDS, 150 mM NaCl, 50 mM Trizma® base, pH 7.4 
 
Up to 50 mg mouse tissue was homogenized in a TissueLyser LT (Qiagen) with a 5 mm metal-ball 
(Qiagen) for 3 min at 50 hertz in 495 µl homogenisation buffer. After addition of 55 µl 
10 x detergent, tissue was incubated on ice for 20 min. Lysates were centrifuged for 20 min at 
16300 g and 4 °C and pellets were discarded.  
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Isolated vessel lysates: 
10x Protease inhibitor (PI): 
1 protease inhibitor tablet in 1 ml H2ODI  
 
RIPA: 
150 mM NaCl, 50 mM Trizma® base, 0.1 % SDS, 1 % NP-40, 0.5 % Sodium deoxycholate, pH 7.4; supplemented with 1 x PI, 50 mM NaF, 
20 mM Na4P2O7, 2 mM Na3VO4 
 
5x Loading buffer: 
30 % glycerol, 6 % (w/v) SDS, 500 mM DTT, 0.03 % (w/v) bromophenol blue, 375 mM Trizma® base, pH 6.8 
 
Isolated vessels from one hemisphere were homogenized in a conical tissue grinder (Wheaton) in 
80 µl RIPA with 30-40 up-and-down strokes. Vessels were incubated on ice for 1 h and lysates were 
centrifuged for 20 min at 16300 g and 4 °C. Pellets were resuspended in 50 µl RIPA with 1 x loading 
buffer, incubated over night at room temperature and centrifuged for 30 min at 16300 g and 11 °C. 
Lysates were collected and stored at -20 °C. 
 
2.6.4  Protein quantification 
Protein concentrations of cell and tissue lysates were determined using the Pierce™ BCA Protein 
Assay kit (Thermo Scientific) according to the manufacturer´s protocol. Absorbance at 562 nm was 
measured with a Multiskan RC plate reader (Thermo / LabSystems). Standards and samples were 
measured in duplicates. Protein concentrations in conditioned MEF cell media was measured with 
a Qubit 2.0 Fluorometer (Life Technologies) using the manufacturer´s manual. 
 
2.6.5  SDS-PAGE 
4x Lower Tris: 
0.4 % (w/v) SDS, 1.5 M Trizma® base, pH 8.8 
 
4x Upper Tris: 
0.4 % (w/v) SDS, 0.5 M Trizma® base, pH 6.8 
 
1x Running buffer: 
25 mM Trizma® base, 192 mM glycine, 1 % (w/v) SDS 
 
5x Loading buffer: 
30 % glycerol, 6 % (w/v) SDS, 500 mM DTT, 0.03 % (w/v) bromophenol blue, 375 mM Trizma® base, pH 6.8 
 
Protein lysates containing equal amounts of protein and conditioned media were size-fractioned by 
denaturing SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in a discontinuous system with a 
1.0 mm thick stacking and separating gel (see Table 2.15) in 1x running buffer. Protein lysates and 
conditioned media were mixed with 5x loading buffer and boiled for 5 min at 95 °C before loading 
onto the gel. 5 µl Precision Plus Protein All Blue Standards (Bio-Rad) was used as a molecular 
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weight marker and electrophoresis was performed with the Mini-Protean® Tetra Cell system (Bio-
Rad) at 80-120 V. 
 
Table 2.15: Composition of SDS-polyacrylamide gels. 
Solution 10 % Separating gel 12.5 % Separating gel Stacking gel 
H2ODI 2.44 ml 1.9 ml 1.47 ml 
Acrylamide 2 ml 2.54 ml 0.276 ml 
4x Lower Tris 1.5 ml 1.5 ml - 
4x Upper Tris - - 556 µl 
APS 50 µl 50 µl 23 µl 
TEMED 5 µl 5 µl 2.3 µl 
 
2.6.6 Western blotting 
Blotting buffer: 
192 mM glycine, 20 % methanol, 25 mM Trizma® base, pH 8.3 
 
1x TBST 
150 mM NaCl, 0.2 % Tween-20, 10 mM Trizma® base, pH 8.0 
 
Blocking solution: 
4 % (w/v) skim milk powder in 1x TBST buffer 
 
After SDS-PAGE, proteins were transferred to an Immobilion-P Membrane (Millipore). The 
membrane was shortly immersed in methanol and incubated for 5 min together with the gel in 
blotting buffer. The protein-transfer was performed by electro-blotting for 1 h at 125 milliampere 
per membrane using blotting buffer in a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad). As a 
loading control proteins were visualized by staining of the membrane with Ponceau-S Solution 
(Sigma). Afterwards, membranes were blocked for 1 h in blocking solution at room temperature to 
inhibit unspecific binding. After incubation with the primary antibody diluted in blocking solution 
overnight at 4 °C, membranes were washed in 1x TBST followed by incubation with the horseradish 
peroxidase (HRP) conjugated secondary antibody in blocking solution for 1 h at room temperature 
or overnight at 4 °C. Then, membranes were washed again with 1x TBST and developed using the 
Immobilon Western Chemiluminescent HRP Substrate (Millipore) according to the manufacturer’s 
instructions. The chemiluminescence signal was detected with the Fusion FX7 (Vilber Lourmat). The 
antibodies used for Western blotting and the respective dilutions are indicated in Tables 2.13 and 
2.14. For quantification, the densities of the bands were determined using the software ImageJ. 
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2.6.7  Proteolysis assay 
Denatured BSA and cell-derived HtrA1: 
Coomassie brilliant blue (CBB) solution: 
5 % Aluminium sulphate, 10 % Ethanol, 0.02 % Coomassie brilliant blue G250, 2 % ortho-Phosphoric acid 
 
0.4 mg/ml BSA, 1.5 mM DTT in PBS was added to conditioned medium from vector, wild-type or 
mutant HtrA1 transfected HEK293T cells and samples were incubated for 24 h at 37 °C. After SDS-
PAGE (see chapter 2.6.5), gels were stained with CBB solution. 
 
LTBP-1 or TGF-β1 and cell-derived HtrA1: 
Conditioned medium from LTBP-1 or TGF-β1 transfected HEK293T cells was mixed with one volume 
of medium from vector, wild-type or mutant HtrA1-transfected HEK293T cells or of concentrated 
medium from MEF cells and samples were incubated for 24 h (72 h for MEF cells) at 37 °C. In some 
assays, 5 mM EDTA or 5 µM NVP-LBG976 was added.  
 
2.6.8  ELISA for TGF-β 
Activation solutions: 
1 N HCl  
1.2 N NaOH, 0.5 HEPES  
 
TGF-β1 concentration was quantified with TGF-beta 1 Quantikine ELISA kit (R&D Systems) using the 
manufacturer’s protocol. To activate latent TGF-β1 to the immunoreactive form, samples were 
acidified followed by neutralization. After incubation of 50 µl MEF cell culture medium or 10 µl 
blood serum with 10 µl or 2.5 µl HCl for 10 min, samples were neutralized with 10 µl or 2.5 µl 
NaOH. TGF-β1 concentration of the activated samples was either measured undiluted (MEF cell 
culture medium) or diluted 60-fold (blood serum). Absorbance at 562 nm and 420 nm was 
measured with a Multiskan RC plate reader (Thermo / LabSystems). 
 
2.6.9  Active TGF-β measurement 
In order to measure active TGF-β in conditioned MEF cell media, an assay using fibroblasts derived 
from TGF-β1-/- mice (MFB-F11 cells), kindly provided by Ina Tesseur (Stanford University School of 
Medicine, Stanford, CA), was applied. These cells were transfected with a reporter plasmid 
containing TGF-β responsive SMAD-binding elements driving the expression of secreted alkaline 
phosphatase (SEAP) (Tesseur et al., 2006). 3x104 MFB-F11 cells per 96-well were seeded and 
incubated overnight. After washing with PBS and incubation of MFB-F11 cells in serum-free DMEM 
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for 2 h, 50 µl of heat activated (10 min at 80 °C) conditioned MEF cell medium, that was collected 
after 24 h, 48 h or 72 h, was added to MFB-F11 cells. SEAP activity was measured after 24 h using 
the Great EscAPe™ SEAP Chemiluminescence kit 2.0 (Clontech) with a GloMax-Multi+ Detection 
System (Promega). The relative amount of bioactive TGF-β (fold induction) is determined based on 
the baseline measurement (no TGF-β). 
 
2.7 Histological stainings of mouse brain cryosections 
2.7.1 Antibodies 
Table 2.16 and Table 2.17 list the primary and secondary antibodies that were used for histological 
stainings. 
 
Table 2.16: Primary antibodies used for immunofluorescence stainings. 
Antibody Type Dilution Source 
Collagen type IV goat polyclonal 1:400 Southern Biotech 
Laminin rabbit polyclonal 1:50 Dako 
Phospho-Smad2 
(Ser465/467) (138D4) 
rabbit monoclonal 1:50 Cell Signaling 
α-Smooth Muscle Actin-Cy3™ mouse monoclonal 1:500 SIGMA 
 
Table 2.17: Secondary antibodies used for immunofluorescence stainings. 
Antibody Conjugate Dilution Source 
Donkey anti-rabbit Cy3 (red) 1:100 Jackson 
Donkey anti-goat Cy2 (green) 1:100 Jackson 
Goat anti-rabbit Alexa Fluor 488 
(green) 
1:100 Invitrogen 
 
 
 
Materials and methods 
38 
2.7.2 Immunofluorescence stainings 
Histo blocking buffer: 
5 % (w/v) BSA in 1x PBS 
 
Dilution buffer: 
0.2 % BSA in 1x PBS 
 
Serial coronal mouse brain sections were prepared using a cryostat (CM1950, Leica) in 7 µm 
thickness and stored at -80 °C until further use. Sections were thawed to room temperature for 15 
min and then fixed for 15 min with PFA under gentle agitation. After washing with PBS, sections 
were blocked with histo blocking buffer for 1h at room temperature. For the detection of 
phosphoSMAD2, sections were additionally permeabilized by adding 0.1 % Triton-X to the histo 
blocking buffer. Primary antibodies were diluted in dilution buffer and sections were incubated 
with the antibodies overnight at 4 °C. After washing with PBS, sections were incubated with the 
fluorescence coupled secondary antibody in dilution buffer for 1.5 h at room temperature and 
washed again. Sections were mounted in ProLong® Gold Antifade Reagent with DAPI (Life 
Technologies) with coverslips. The antibodies and the respective dilutions are indicated in Tables 
2.16 and 2.17. Regions of interest were analyzed with the Axiovert 200M Fluorescence Microscope 
(Zeiss). Quantitative comparisons on sections from mutant and wild-type mouse brains were 
performed in parallel using the same settings of digital images for each brain region. Quantification 
of immunofluorescence stainings was performed using the software ImageJ. Collagen IV-, 
phosphoSMAD2- and α-SMA-immunopositive area was expressed as a percentage of the total 
image area.  
For the detection of α-SMA, cryo sections derived from 20-26 old HtrA1+/+(gt) and HtrA1-/-(gt) 
mouse brains taken -0.50 to 1.20 mm to the midline (in total 3 areas) according to the mouse brain 
atlas (Paxinos and Franklin, 2001) were probed with an α-SMA antibody and co-stained with 
laminin (one section per mouse per area).  
For the detection of collagen IV and phosphoSMAD2, brain sections derived from 20-26 old 
HtrA1(gt) animals taken -1.50 to 1.70 mm to the midline (in total 6 areas) according to the mouse 
brain atlas (Paxinos and Franklin, 2001) were probed with a collagen IV or phosphoSMAD2 
antibody (one section per mouse per area). 
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2.7.3 Klüver-Barrera Luxol fast blue staining 
Luxol solution: 
0.1 % Luxol fast blue in 95 % Ethanol, after dissolution addition of 0.0005 % acetic acid; filtration. 
 
Cresyl violet solution: 
0.1 % Cresyl violet acetate in H2ODI, after dissolution addition of 0.001 % acetic acid; filtration. 
 
Lithium Carbonate solution: 
0.025 % Lithium Carbonate in H2ODI 
 
Serial coronal mouse brain sections were prepared using a cryostat (CM1950, Leica) in 7 µm 
thickness and stored at -80 °C until further use. Sections taken -2.30 to 1.10 mm to the midline 
according to the mouse brain atlas (Paxinos and Franklin, 2001) were thawed to room temperature 
for 15 min and then dipped for 30 s in 96 % Ethanol. After staining of myelin sheaths with Luxol 
solution for 1 h at room temperature under gentle stirring, sections were rinsed with H2ODI and 
differentiated for 30 s in Lithium Carbonate solution and 30 s in 70 % Ethanol. Sections were 
washed again in H2ODI and cell bodies were stained with Cresyl violet solution for 10 min at room 
temperature. Sections were washed with H2ODI, dipped for 5 s in 96 % Ethanol and for 10 s in 99 % 
Ethanol and finally mounted in Eukitt® (Fluka) with coverslips. Regions of interest were analyzed 
with the Axio Imager.M2 Microscope (Zeiss). Comparisons on sections from mutant and wild-type 
mouse brains (two sections per mouse per area, in total 5 areas) were performed in parallel using 
the same settings of digital images for each brain region. Alterations in myelin structure were 
determined semi-quantitatively by visual inspection of stained sections: 1, structured organization 
of myelin sheaths; 2, partially disorganized myelin sheath; 3, disorganization of myelin sheaths. 
Vacuolisation was also determined semi-quantitatively by visual inspection: 1, no vacuoles; 2, a few 
vacuoles; 3, several vacuoles. 
 
2.8 Statistical analysis 
Quantitative data are represented as mean values and standard error of the mean (SEM) of the 
indicated number of experiments. Statistical analysis was performed applying the Mann-Whitney 
Test with the SigmaPlot 12.5 Software. Significance is depicted with stars: *: p < 0.05; **: p < 0.01; 
***: p < 0.001. 
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3 Results 
3.1 Description of HtrA1-/- mice 
In 2009, Hara et al. demonstrated that loss-of-function mutations in the HTRA1 gene cause the 
recessively inherited small vessel disease (SVD) CARASIL. The same group proposed that the 
transforming growth factor beta (TGF-β) signaling pathway plays a key role in CARASIL 
pathogenesis. To learn more about the molecular mechanisms underlying this disorder, especially 
the link between HtrA1 and TGF-β, HtrA1 knockout (HtrA1-/-) mice, that have not been 
characterized in literature at the beginning of this thesis, were analyzed. Initially, a newly 
generated mouse strain carrying an HTRA1 allele interrupted by gene trapping (gt) was available 
(HtrA1(gt) mice). During the course of this thesis we got access to a second HtrA1 null strain 
created previously through targeted mutation (tm) (Jones et al., 2011, Zhang et al., 2012). This 
strain (HtrA1(tm) mice) was used to verify and complement the results of the trapped strain.  
 
3.1.1 The HtrA1(gt) strain 
A mouse embryonic stem (ES) cell clone (129/SvEvBrd strain) carrying one HTRA1 allele interrupted 
by the insertion of the OmniBank® Gene Trapping vector VICTR 48 within the first intron had been 
generated as part of a high-throughput gene trapping approach (see also chapter 2.4.1) 
(Zambrowicz et al., 2003). Microinjection of ES cells into C57BL/6J blastocysts and subsequent 
breeding of chimeras with wild-type mice (C57BL/6J strain) resulted in the generation of 
heterozygous offspring with a mixed genetic background (129/SvEvBrd and C57BL/6J). These mice 
were obtained from Lexicon Genetics/Taconic (Woodlands, TX; New York) and bred to 
homozygosity. 
VICTR 48 contains a splice acceptor (SA) followed by a neomycin selection marker (NEO) and a 
transcript-terminating polyadenylation signal (pA) (Figure 3.1 A). Thus, a transcript driven by the 
HTRA1 promoter that encodes only the first HTRA1 exon and the NEO sequence is generated from 
the trapped allele (Figure 3.1 A, left transcript). Exons 2-9 are not included in this HTRA1 transcript 
resulting in a loss of HtrA1 protein function. However, together with the partial first exon of the 
murine Bruton’s tyrosine kinase (BTK) gene they are part of a transcript initiated by the ES 
cell-specific phosphoglycerate kinase (PGK) promoter which is used for the identification of 
sequence tags from the mutated genes. The presence of termination codons in all three reading 
frames prevents the translation of HTRA1 exons (Figure 3.1 A, right transcript). 
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Genotyping of HtrA1(gt) mice was performed by PCR using the primer pairs depicted in Figure 3.1 A 
(grey arrows). Amplification resulted in the generation of a 434 bp fragment for the wild-type (WT) 
locus and a 281 bp fragment for the mutant locus (Figure 3.1 B). 
 
Figure 3.1: Genomic structure followed transcription and translation, and genotyping of the mouse HTRA1 gene in 
HtrA1
-/-
(gt) mice. (A) Depicted are HTRA1 exons (light blue boxes numbered 1-9) and localization of the OmniBank® Gene 
Trapping vector VICTR 48 (black triangle) containing a splice acceptor (SA) and splice donor site (SD). LTR: long terminal 
repeat; NEO: neomycin-resistance cassette; pA: polyadenylation signal; SV40tPA: SV40 polyadenylation signal; 
PGK: phosphoglycerate kinase 1 promoters; BTK: Bruton´s tyrosine kinase exon 1; light grey boxes: untranslated region; 
black arrows: promoter; grey arrows: primers used for genotyping. Upon transcription two primary transcripts occur, the 
first contains HTRA1 exon 1 and NEO, the second BTK (contains stop codons in all reading frames) and HTRA1 exons 2-9. 
Translated is only the first transcript, while the second one contains only parts of BTK. Curved lines depict proteins. 
(B) Genotyping by PCR revealed a wild-type (WT) band of 434 bp (primers TF1102-5´and TF1102-3´) and a mutant band of 
281 bp (primers TF1102-5´ and LTR-rev; see Table 2.3). +/+: wild-type; +/-: heterozygous; -/-: knockout. 
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We verified inactivation of the trapped allele on mRNA level by PCR with different primer pairs 
(arrows, Figure 3.2 A). Using primers spanning exons 1 through 6 including the gene trap insertion 
site, a band of 672 bp was amplified in kidney tissues derived from HTRA1+/+(gt) and HTRA1+/-(gt) 
mice (Figure 3.2 B, left panel). However, no transcript was detected in HTRA1-/-(gt) mice 
demonstrating the interruption of the trapped allele. Similar results were obtained with primer 
pairs spanning exons 2 through 6 (middle panel, Figure 3.2 B), or exons 6 through 9 (right panel, 
Figure 3.2 B) yielding PCR products of 559 bp and 309 bp. This was confirmed in other tissues 
including brain and lung (see Fig. 3.3).  
 
Figure 3.2: Loss of HtrA1 mRNA expression in HtrA1
-/-
(gt) mice. (A) Genomic structure of the mouse HTRA1 gene with 
exons depicted as light blue boxes. Arrows indicate the position of the primers (see Table 2.3); the black triangle 
represents the localization of the gene trapping vector. (B) HtrA1 mRNA expression was analyzed in kidney samples using 
three different primer pairs. None of them amplified a detectable band in HtrA1
-/-
(gt) mice. Exon 1-6 and 2-6 fragments 
were visualized by the QIAxcel capillary electrophoresis system (Qiagen), exon 6-9 fragments by regular agarose gel 
electrophoresis. 
 
To quantify HtrA1 mRNA expression levels, real-time PCR was performed on brain, kidney and lung 
samples using primers spanning exons 6 to 9. While no transcripts were detected in homozygous 
knockout mice, HtrA1 mRNA expression was reduced to about 50 % in heterozygous mice (Figure 
3.3 A). A verification of HtrA1 deficiency in mouse tissues on protein level was only possible upon 
combined immunoprecipitation/immunoblotting performed by N. Beaufort (ISD, Munich) due to 
low HtrA1 expression levels in the wild-type mice (Beaufort et al., 2014). In cell lysates and 
concentrated supernatants of mouse embryonic fibroblasts HtrA1 protein was detected by 
common Western blotting (see chapter 3.4.3.1) and the knockout validated. 
HtrA3 and HtrA4 share extensive homology with HtrA1 (see Figure 1.5) and might have redundant 
activities (Clausen et al., 2002). We investigated their mRNA expression levels by real-time PCR in 
brain tissue and observed no significant changes (Figure 3.3 B). These data demonstrated the 
absence of compensation on mRNA level in HtrA1(gt) deficient mice.  
Results 
43 
 
Figure 3.3: HtrA1, HtrA3 and HtrA4 mRNA expression analysis in HtrA1(gt) mice. (A) Relative HtrA1 mRNA levels from 
brain, kidney and lung samples isolated from HtrA1(gt) mice were determined by real-time PCR (β-Actin was used for 
normalization) using primers spanning exon 6 to 9. n=3. (B) HtrA3 or HtrA4 mRNA levels of brain samples isolated from 
HtrA1(gt) mice were normalized to β-Actin mRNA levels. n=6; results are expressed as mean ±SEM and are not significant 
as determined by Mann-Whitney Rank Sum Test 
 
3.1.2 The HtrA1(tm) strain 
During the course of this thesis we got access to a second HtrA1 knockout mouse model 
(HtrA1(tm); see also chapter 2.4.1), which had previously been generated by C. Oka (Nara Institute 
of Science and Technology, Japan) (Jones et al., 2011, Zhang et al., 2012). This strain provided us 
with the opportunity to confirm findings in an independent model. In contrast to HtrA1(gt) mice, 
this strain had been backcrossed over several generations. To precisely determine the 
homogeneity of the genetic background, 1449 SNP (single nucleotide polymorphism) markers 
across 19 autosomes as well as the X chromosome were genotyped representatively in two animals 
(Taconic, New York). They were found to be 98.3 and 99.1 % identical to the C57BL/6J strain 
Brain LungKidney
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
+/+ +/- -/- WT HET KO WT HET KO
R
e
la
ti
v
e
 H
tr
A
1
 m
R
N
A
 l
e
v
e
l
+/+      +/- -/- +/+      +/- -/- +/+      +/- -/-
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
WT KO
R
e
la
ti
v
e
 H
tr
A
3
 m
R
N
A
le
v
e
l
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
WT KO
R
e
la
ti
v
e
 H
tr
A
4
 m
R
N
A
le
v
e
l
+/+       -/- +/+       -/-
Brain Brain
A
B
Results 
44 
demonstrating a fairly homogenous genetic background equivalent to approximately six 
backcrosses (Markel et al., 1997). 
This strain had been created by homologous recombination with a gene targeting vector containing 
an IRES-lacZ reporter element as well as a neomycin-resistance sequence (NEO) followed by a 
transcript-terminating polyadenylation signal (pA) which causes the exclusion of most of exon 1 
sequence including the ATG initiation codon (Figure 3.4 A). Thus, no HtrA1 protein can be 
translated from the transcript driven by the endogenous HTRA1 promoter. 
Genotyping of HtrA1(tm) mice was performed by PCR using primer pairs located within exon 1 
(WT allele) and the NEO cassette (mutant allele) resulting in fragment sizes of 297 bp and 280 bp 
respectively (Figure 3.4 B). 
 
Figure 3.4: Genomic structure and genotyping of the mouse HTRA1 gene in HtrA1
-/-
(tm) mice (adapted from Jones et al. 
(2011)). (A) Depicted are HTRA1 exons (light blue boxes numbered 1-9) and the targeting vector containing an IRES-lacZ 
reporter element, a neomycin-resistance sequence (NEO) and a SV polyadenylation signal (pA). Light grey boxes: 
untranslated region; grey arrows: primers used for genotyping. (B) Genotyping by PCR revealed a WT band of 297 bp and 
a mutant band of 280 bp (for primers see Table 2.3)  
 
Like in HtrA1(gt) mice, inactivation of the targeted allele was verified on mRNA level by real-time 
PCR using primers spanning exons 6 to 9. Again, no HtrA1 transcripts were detected in lung 
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samples of HtrA1-/- animals (Figure 3.5 A). Furthermore, HtrA3 and HtrA4 mRNA levels were not 
elevated in HtrA1-/-(tm) mice but even reduced (Figure 3.5 B).  
 
Figure 3.5: HtrA1, HtrA3 and HtrA4 mRNA expression analysis in HtrA1(tm) mice. (A) Relative HtrA1 mRNA levels of lung 
samples isolated from HtrA1(tm) mice were determined by real-time PCR (β-Actin was used for normalization) using 
primers spanning exons 6 to 9. n=3-4. (B) HtrA3 or HtrA4 mRNA levels of brain samples isolated from HtrA1(tm) mice 
were normalized to β-Actin mRNA levels. n=7-9; results are expressed as mean ±SEM; * p < 0.05, Mann-Whitney Rank 
Sum Test. 
 
In summary, these data demonstrated the absence of HtrA1 expression in the HtrA1(gt) as well as 
HtrA1(tm) mouse strain. Furthermore, no signs of compensation by other HtrA family members 
were observed. We therefore continued by analyzing the consequences of HtrA1 deficiency. 
The results presented in the following sections were obtained with HtrA1(gt) mice unless stated 
otherwise. 
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3.1.3 Basic characterization of HtrA1-/- mice 
Our initial analyses performed on adult animals (see chapter 3.1.1 and 3.1.2) indicated that 
HtrA1-deficient mice are viable. To confirm this statistically the genotypes of 100 offspring from 
heterozygous parents were determined (Table 3.1). The numbers obtained were in agreement with 
a Mendelian distribution demonstrating the absence of embryonic lethality. 
 
Table 3.1: Mendelian inheritance of HtrA1 mice. The numbers represent the percentages of genotypes determined from 
100 individuals with heterozygous parents. 
Genotype +/+ +/- -/- 
Inheritance HtrA1 25 % 53 % 22 % 
 
Furthermore, breeding of homozygous mice produced normal litter sizes demonstrating no 
impairment of fertility. 
Next, we analyzed the body weight of 10 and 24 months old mice. Neither in male nor in female 
HtrA1-/- animals differences were observed relative to wild-type animals (Figure 3.6).  
 
Figure 3.6: Body weight of HtrA1
-/-
 mice was similar to age-matched wild-type littermates. Body weight of 10 months 
(n=4) or 24 months old (n=4-6) female and 10 months (n=1-5) or 24 months old (n=2-4) male HtrA1 mice was measured. 
Results are expressed as mean ±SEM and are not significant as determined by Mann-Whitney Rank Sum Test. 
 
In order to assess the survival over time, a Kaplan-Meier curve was generated (Figure 3.7). Mice 
sacrificed at specific time points were not included. Even though a higher lethality was observed for 
HtrA1-/- mice in the first year, this finding was not significant. Overall, the lifespan of 
HtrA1-deficient animals was comparable to that of wild-type littermates.  
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Figure 3.7: Kaplan-Meier survival curve. The x-axis depicts the age of the mice in days. The y-axis depicts the fraction of 
survival in %. n=10-19; ANOVA on Ranks statistical test found no significant difference between the three groups. 
 
In summary, HtrA1-/- mice did not show abnormalities with respect to embryonic and adult survival, 
inheritance, litter size or body weight. 
 
3.2 Analysis of extraneurological CARASIL symptoms 
Typical extraneurological manifestations of CARASIL patients are spondylosis, kyphosis and 
alopecia (Fukutake, 2011, Yanagawa et al., 2002). Thus, we investigated these features in aged 
HtrA1-/-(tm) mice. 
3.2.1 No alopecia in HtrA1-/- mice 
Behavior-associated hair loss (so-called “overgrooming” or whisker/hair and fur trimming, nibbling 
as well as eating) has long been observed in laboratory mice (Long, 1972, Sarna et al., 2000, Strozik 
and Festing, 1981), and alopecia is common in mouse and human aging (Novak and Meyer, 2009, 
Trifunovic et al., 2004). Nevertheless, we analyzed alopecia in 19-20 months old HtrA1(tm) mice by 
visual inspection. Quantification was performed by photographing the animals and ranking the 
degree of hair loss on a scale from 0 (no alopecia) to 3 (severe alopecia). Figure 3.8 A shows 
examples of mice with completely intact fur (left pictures) as well as of mice with areas of alopecia 
(right pictures). Especially hair loss at the area around the nose, which is typical for laboratory 
mice, was found in almost all animals (Figure 3.8 B). When hair loss was evaluated separately at the 
body, head and snout, HtrA1-/- mice did not show alopecia to a stronger degree compared to their 
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heterozygous or wild-type littermates (Figure 3.8 C). However, due to the difficulty of assessing 
specific hair loss, the relevance of this analysis should not be considered too high.  
 
Figure 3.8: Alopecia in HtrA1(tm) mice. 19-20 months old mice were photographed and evaluated for alopecia by visual 
inspection. (A, B) Arrows indicate areas of hair loss at the whole body (A) or at the snout (B). (C) Quantification of 
alopecia. Severity of alopecia was evaluated semi-quantitatively on a scale from 0 (no alopecia) to 3 (severe alopecia). 
n=6-12; results are expressed as mean ±SEM and are not significant as determined by Mann-Whitney Rank Sum Test. 
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3.2.2 No spondylosis in HtrA1-/- mice 
To investigate skeletal abnormalities, 18-19 months old HtrA1(tm) mice were checked for 
dysmorphology by X-ray examination in a Faxitron MX-20 (collaboration with the German Mouse 
Clinic, Neuherberg, Germany). The following parameters were screened: skull shape; orbit; 
mandible, maxilla, teeth; vertebrae (cervical, thoracic, lumbar, sacral and caudal; for number and 
shape); scapulas, clavicle, humerus, ulna, radius; ribs (for number and shape); pelvis; femur (for 
diameter and shape); tibia, fibula; digits (for number and completeness); and joints. HtrA1-/- mice 
did not show abnormalities concerning any of these parameters. In addition, no spondylotic 
differences between wild-type and knockout animals were detected (Figure 3.9 A). Some animals 
displayed kyphosis (Figure 3.9 B, C), a well-known aging-related phenotype in humans and rodents 
(Katzman et al., 2010, Trifunovic et al., 2004), and/or scoliosis (Figure 3.9 D), conditions that are 
associated with spondylosis. However, these alterations were observed in animals of all genotypes 
and no significant differences could be found in HtrA1-deficient mice. 
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Figure 3.9: X-ray analysis. 18-19 months old HtrA1(tm) mice were analyzed by X-ray. (A) No spondylosis deformans in 
HtrA1(tm) mice. (B, D) Some animals showed kyphosis (B, right panels), normal spine shape (B, left panels) and/or 
scoliosis (D) in a genotype independent manner. (C) Quantification of kyphosis. Severity of kyphosis was evaluated semi-
quantitatively by visual inspection of X-ray pictures: 0, no kyphosis; 3, severe kyphosis. n=7-12; results are expressed as 
mean ±SEM; * p < 0.05, Mann-Whitney Rank Sum Test. 
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3.3 Analysis of cerebral CARASIL symptoms 
3.3.1 Reduction of cerebral α-smooth muscle actin (α-SMA) expression in 
HtrA1
-/-
 mice 
CARASIL represents an arteriopathy characterized by the loss of vascular smooth muscle cells 
(vSMCs) in cerebral small vessels (Oide et al., 2008). To investigate whether this pathological 
feature is recapitulated in HtrA1-deficient mice, we quantified mRNA levels of the vSMC marker 
α-smooth muscle actin (α-SMA) in brains from 2, 12 and 18-26 months old mice by real-time PCR. 
While α-SMA mRNA was similar in 2 months old HtrA1+/+ and HtrA1-/- mice, we found a trend 
towards lower levels in 12 months old HtrA1-/- animals (Figure 3.10). In 18-26 months old mice, we 
detected a significant reduction of ~50 % in Htra1-deficient animals.  
 
 
Figure 3.10: Decreased cerebral α-SMA mRNA expression in aged HtrA1
-/-
 animals. α-smooth muscle actin (α-SMA) 
mRNA levels of brain samples isolated from 2, 12 and 18-26 months old HtrA1 mice were determined by real-time PCR 
and normalized to β-Actin. 2 months: n=4-7; 12 months: n=5-6; 18-26 months: n=7-10; results are expressed as mean 
±SEM; * p < 0.05 Mann-Whitney Rank Sum Test. 
 
Next, we examined α-SMA protein levels by quantification of Western blot signals normalized to 
β-Actin (same mice that were used for mRNA analysis were partially also used for further α-SMA 
studies). In 2 months old knockout mice we detected increased α-SMA expression levels 
(Figure 3.11). In contrast, a reduction was observed in 12 and 20-26 months old HtrA1-/- animals. 
These results are similar to those observed by real-time PCR and show that aged HtrA1-deficient 
mice display less α-SMA expression. 
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Figure 3.11: Reduction of α-SMA protein expression in brains of aged HtrA1
-/-
 mice. (A) α-SMA protein levels were 
analyzed by immunoblotting of equal amounts of brain samples derived from 2, 12 or 20-26 months old HtrA1 mice using 
an α-SMA antibody (42 kDa; upper panels). Detection of β-Actin expression (42 kDa; lower panels) was used for 
normalization. (B) α-SMA protein levels were normalized to β-Actin. 2 months, 12 months: n=3; 20-26 months: n=6; 
results are expressed as mean ±SEM and are not significant as determined by Mann-Whitney Rank Sum Test. 
 
To further investigate this finding, we probed cerebral coronal cryo sections derived from the 
20-26 months old animals that also underwent α-SMA mRNA and protein analysis with an α-SMA 
antibody and co-stained with laminin to visualize the vessels (one section per mouse per area, in 
total 2 areas). Figure 3.12 depicts representative images showing α-SMA expressing vessels in a 
larger magnification (Figure 3.12 A) and a lower magnification (Figure 3.12 B). Upon quantification 
of total stained area (Figure 3.12 C) and the number of α-SMA immunopositive vessels per picture 
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(0.6 mm2; taken with a 10 x objective; Figure 3.12 D) we found a significant difference between 
wild-type and knockout mice in the corpus callosum (cc) and a clear trend in the cortex: cerebral 
α-SMA immunopositive areas in the vessels as well as the vessel number were decreased in 
knockout animals. 
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Figure 3.12: Decreased α-SMA levels in aged HtrA1 knockout animals demonstrated by immunohistochemistry. 
(A, B) One brain hemisphere per 20-26 months old HtrA1 mouse was cut coronally and sections were stained with an 
α-SMA antibody (red) and co-stained with an Laminin antibody (green). Pictures show representative α-SMA stainings of 
vessels of the corpus callosum taken with a 40 x objective (A) or with a 10 x objective (B). (C) Quantification of the α-SMA 
immunopositve area in the corpus callosum (cc) and cortex of 20-26 months old HtrA1
-/-
 compared to HtrA1
+/+
 mice 
expressed as a percentage of the total image area. (D) Number of α-SMA immunopositve vessels per image (0.6 mm
2
; 
taken with a 10 x objective; counted manually, false-positive background-artifacts were excluded by co-localization with 
the laminin staining) in the cc and cortex of 20-26 months old HtrA1
-/-
 compared to HtrA1
+/+
 mice. n=6; results are 
expressed as mean ±SEM; * p < 0.05, Mann-Whitney Rank Sum Test. 
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In summary, α-smooth muscle actin expression is reduced in aged HtrA1-/- mouse brains on mRNA 
and protein level. 
 
3.3.2 Decreased cerebral type IV collagen expression in aged HtrA1-/- mice 
Another characteristic feature of CARASIL is a reduced immunoreactivity of the basal lamina 
protein type IV collagen in the cerebrovasculature (Oide et al., 2008). In order to evaluate collagen 
IV expression in our mouse model, we measured its protein levels in various brain regions of aged 
animals via immunohistochemistry (one brain section per mouse per area, in total 6 areas). As 
CARASIL is primarily a disease of the WM (Fukutake, 2011), mainly these regions were investigated 
separately (anterior commissure, anterior part; corpus callosum including forceps minor of the 
corpus callosum; internal capsule; fimbria of the hippocampus), but also two grey matter regions 
(cortex; hippocampus). Figure 3.13 A shows representative type IV collagen stainings from the 
corpus callosum of an HtrA1+/+ (upper panels) and HtrA1-/- (lower panels) mouse brain. After 
quantification, a reduction was observed in HtrA1-deficient animals in most areas, but significance 
was reached only in cc, aca and cortex (Figure 3.13 B). However, counting the number of collagen 
IV immunopositive vessels per picture revealed no differences indicating a decrease of basal lamina 
thickness per vessel (Figure 3.13 C). Note, that the vascular density is higher in the cortex than in 
the white matter regions. This can be explained by the fact that neurons, mainly present in grey 
matter regions including the cortex, have a far higher demand of oxygen and nutrients than white 
matter regions and thus are better supplied with blood (Cavaglia et al., 2001).  
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Figure 3.13: Aged HtrA1
-/-
 mouse brains show a reduced type IV collagen expression. (A) Brain sections of 20-26 months 
old HtrA1 mice were stained with collagen IV antibody (green) and nuclei were visualized with DAPI (blue). Pictures show 
a representative staining of the corpus callosum. (B) Quantification of the collagen IV immunoreactive area in the corpus 
callosum (cc), forceps minor of the corpus callosum (fmi), internal capsule (ic), anterior commissure, anterior part (aca), 
fimbria of the hippocampus (fi), hippocampus (hippoc.) or cortex of 20-26 months old HtrA1
-/-
 compared to HtrA1
+/+
 mice 
expressed as a percentage of the total image area. (C) Number of collagen IV immunopositve vessel counts per image 
(0.15 mm
2
; taken with a 20 x objective) in different brain areas of 20-26 months old HtrA1
-/-
 compared to HtrA1
+/+
 mice. 
n(animals)=6; n(evaluated sections per genotype)=6-34; results are expressed as mean ±SEM; * p < 0.05, *** p < 0.001, 
Mann-Whitney Rank Sum Test. 
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3.3.3 No white-matter vacuolization but diffuse demyelination in HtrA1-/- 
mouse brains 
The most characteristic MRI finding in CARASIL patient brains are white-matter lesions (Fukutake 
and Hirayama, 1995). In mice such lesions can be visualized histologically by Klüver-Barrera Luxol 
fast blue staining followed by quantification of brain vacuolization as demonstrated in the CADASIL 
mouse model (Joutel et al., 2010). We therefore stained coronal cryo sections of 20-26 months old 
HtrA1 animals with Klüver-Barrera Luxol fast blue staining to visualize lesions, white matter 
structure and myelin (two sections per mouse per area, in total 5 areas). The regions of interest 
(corpus callosum; internal capsule; anterior commissure, anterior part) were analyzed separately 
and images were evaluated semi-quantitatively with respect to the presence of vacuoles by visual 
inspection (see chapter 2.7.3). We hardly detected any vacuoles in the investigated brain regions of 
transgenic mice as well as of age-matched non-transgenic littermates (Figure 3.14). Figure 3.14 A 
shows representatively the occurrence of very few lesions (arrows) in the corpus callosum of an 
HtrA1+/+ and an HtrA1-/- mouse. However, HtrA1-/- mice did not display a higher number of vacuoles 
than their wild-type littermates (Figure 3.14 B). 
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Figure 3.14: White-matter vacuolization in HtrA1 mice. (A) Brain sections of 20-26 months old HtrA1 mice were stained 
with Klüver-Barrera Luxol fast blue staining (myelin appears in blue, nuclei in purple). Pictures show representative 
stainings of the corpus callosum. Arrows indicate the position of the vacuoles. (B) Semi-quantitative quantification of 
vacuoles in the corpus callosum (cc), internal capsule (ic) and anterior commissure, anterior part (aca) by visual 
inspection: 0, no vacuoles; 1, a few vacuoles; 2, several vacuoles. n(animals)=6; cc: n(evaluated pictures per 
mouse)=16-22; ic: n(evaluated pictures per mouse)=1-4; aca: n(evaluated pictures per mouse)=2-4; results are expressed 
as mean ±SEM and are not significant as determined by Mann-Whitney Rank Sum Test.  
 
Moreover, as diffuse myelin loss in the cerebral WM is also typical for CARASIL patients (Arima et 
al., 2003), we investigated the structure of myelin sheaths upon Klüver-Barrera Luxol fast blue 
staining of coronal sections of 20-26 months old mice. We found disorganized myelin fibers with 
diffuse demyelination in HtrA1-/- mouse brains (Figure 3.15 A; see also Figure 3.14 A), that was 
significant after quantification (Figure 3.15 B). In contrast, control mice showed nearly intact 
myelin. 
Results 
59 
 
Figure 3.15: Disorganized myelin sheaths with diffuse demyelination in HtrA1
-/-
 mice. (A) Brain sections of 
20-26 months old HtrA1 mice were stained with Klüver-Barrera Luxol fast blue staining; myelin appears in blue, nuclei in 
purple. Pictures show a representative staining of the corpus callosum. (B) Quantification of disorganized myelin sheaths 
in the corpus callosum of 20-26 months old HtrA1
-/-
 compared to HtrA1
+/+
 mice. Alterations in myelin structure were 
determined semi-quantitatively by visual inspection of stained sections: 1, structured organization of myelin sheaths; 
2, partially disorganized myelin sheaths; 3, disorganization of myelin sheaths. n(animals)=6; n(evaluated pictures per 
mouse)=20; results are expressed as mean ±SEM; *** p < 0.001, Mann-Whitney Rank Sum Test. 
 
In summary, the histological examination of brains from aged HtrA1-/- mice provided evidence for 
white matter changes and a reduction of vessel marker proteins indicating the presence of 
pathological alterations similar to those observed in CARASIL patients.  
 
3.4 Consequences of HtrA1 deficiency on TGF-β signaling 
HtrA1 has previously been associated with the transforming growth factor beta (TGF-β) signaling 
pathway (Launay et al., 2008, Oka et al., 2004). Accordingly, TGF-β activity was reported to be 
altered in cerebral arteries of CARASIL patients (Hara et al., 2009, Shiga et al., 2011). Therefore, we 
set out to analyze the consequences of HtrA1 deficiency on TGF-β signaling in HtrA1-/- mice. 
 
3.4.1 Decreased TGF-β signaling in brains of HtrA1-/- mice 
The TGF-β life cycle consists of various phases including ligand synthesis and secretion, storage 
within the extracellular matrix, release of the active ligand and activation of an intracellular 
signaling cascade resulting in transcriptional alterations (see Figure 1.6). Therefore, pathway 
activity was examined at several levels.  
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First, we analyzed SMAD2 phosphorylation, an intracellular indicator of TGF-β activity (see chapter 
1.4), by Western blotting using an antibody recognizing the phosphorylated forms of SMAD2 
(~60 kDa) and SMAD3 (~50 kDa). In brain lysates of aged mice, a single band of ~60 kDa was 
observed indicating the presence of predominantly SMAD2 (Figure 3.16 A). In the representative 
blot shown, the phosphoSMAD2 signal was decreased in all three HtrA1-/- animals tested. 
Quantification of the signals from 6 mice per group and normalization to β-Actin showed that this 
reduction is significant (Figure 3.16 B). Total SMAD2 levels could not be clearly detected in these 
samples. However, SMAD2 mRNA analysis revealed that expression levels were similar in brains of 
HtrA1+/+ and HtrA1-/- mice (Figure 3.16 C). 
 
Figure 3.16: Decreased phosphorylation of SMAD2 in HtrA1
-/-
 mouse brains. (A, B) PhosphoSMAD2 levels (60 kDa) were 
analyzed by immunoblotting of brain lysates derived from 20-26 months old HtrA1 mice using a phosphoSMAD2 antibody 
(A, representative blot) and normalized to β-Actin (42 kDa) (B). (C) Relative SMAD2 mRNA levels from mouse brains used 
for phosphoSMAD2 analysis were determined by real-time PCR (β-Actin was used for normalization). n=6; results are 
expressed as mean ±SEM; ** p < 0.01, Mann-Whitney Rank Sum Test.  
 
To allow the localization of the phosphoSMAD2 signal within mouse brains we performed 
immunohistological stainings. We probed coronal cryo sections from different regions of HtrA1+/+ 
and HtrA1-/- mouse brains with a phosphoSMAD2 antibody (one section per mouse per area, in 
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total 5 areas; n(WT, KO)=5-6). As damages in CARASIL brains are predominantly detected in WM 
regions, they were mainly investigated (anterior commissure, anterior part; corpus callosum 
including forceps minor of the corpus callosum; internal capsule; fimbria of the hippocampus), but 
also two grey matter regions (cortex; hippocampus). Figure 3.17 A shows a representative 
phosphoSMAD2 staining taken from corpus callosum of an HtrA1+/+ (upper images) and an HtrA1-/- 
mouse brain (lower images). Phosphorylated SMAD2 translocates to the nucleus, thus the 
phosphoSMAD2 staining (in red) co-localizes with the nuclear DAPI staining (in blue). As the corpus 
callosum is a white matter region, labeled cells likely represent predominantly glial cells such as 
astrocytes and oligodendrocytes. Upon quantification, a significant decrease in phosphoSMAD2 
staining was observed in HtrA1-deficient mice (Figure 3.17 B). A similar result was obtained in the 
forceps minor, internal capsule and cortex. While a trend was seen in the anterior commissure, no 
clear differences were seen in hippocampal regions. 
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Figure 3.17: Reduced phosphoSMAD2 levels in HtrA1-deficient brains detected by immunohistochemistry. (A) Brain 
sections of 20-26 months old HtrA1 mice were stained with phosphoSMAD2 antibody (red) and nuclei were visualized 
with DAPI (blue). Pictures show representative phosphoSMAD2 stainings of the corpus callosum. (B) Representative 
quantification of the phosphoSMAD2 immunopositve area in the corpus callosum (cc), forceps minor of the corpus 
callosum (fmi), internal capsule (ic), anterior commissure, anterior part (aca), fimbria of the hippocampus (fi), 
hippocampus (hippoc.) or cortex of 20-26 months old HtrA1
-/-
 compared to HtrA1
+/+
 mice expressed as a percentage of 
the total image area. n=5-6; results are expressed as mean ±SEM; * p < 0.05, ** p < 0.01 Mann-Whitney Rank Sum Test. 
 
In order to confirm these effects on a different TGF-β pathway level, we analyzed mRNA levels of 
connective tissue growth factor (CTGF), a well-known TGF-β target gene with an important role in 
angiogenesis (Chen et al., 2000), in whole mouse brains. Again a significant reduction was observed 
in aged (18-26 months) HtrA1-/- mice (Figure 3.18). A similar result was obtained in younger mice 
with a significant decrease at 2 months of age and a clear trend at 12 months (p = 0.052). This not 
only confirmed reduced TGF-β signaling activity upon HtrA1 ablation, but also indicated a 
dysregulation already at a very young age.  
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Figure 3.18: Decreased TGF-β target gene expression in HtrA1-/- mouse brains. Relative connective tissue growth factor 
(CTGF) mRNA levels from 2, 12 and 18-26 months old HtrA1 mouse brains were determined by real-time PCR and 
normalized to β-Actin. 2 months: n=4-7; 12 months: n=5-6; 18-26 months: n=7-10; results are expressed as mean ±SEM; 
* p < 0.05, ** p < 0.01 Mann-Whitney Rank Sum Test. 
 
We further investigated whether the observed effect on TGF-β signaling is systemic or restricted to 
brain tissue. Blood serum obtained from young and aged mice was analyzed for circulating TGF-β1 
concentrations using an ELISA. A similar analysis had been performed previously in a mouse model 
for Marfan syndrome (Matt et al., 2009), a hereditary connective tissue disorder also associated 
with a TGF-β dysregulation (Judge et al., 2004, Ng et al., 2004). In contrast to this study, we were 
unable to detect significant differences in blood TGF-β1 levels between 6 months old HtrA1-/-(tm) 
or 20-26 months old HtrA1-/-(gt) and age-matched wild-type littermates (Figure 3.19). Note, that 
TGF-β1 concentrations increased with age, an effect that was also seen by Matt et al. (2009).  
 
Figure 3.19: TGF-β concentration in serum of HtrA1
-/-
 mice is not altered compared to HtrA1
+/+
 mice. Total TGF-β1 
concentrations in ng/ml were determined in serum from 6 months old HtrA1(tm) mice (n=7-10) and 20-26 months old 
HtrA1(gt) animals (n=5-6) using an ELISA. Results are expressed as mean ±SEM and are not significant as determined by 
Mann-Whitney Rank Sum Test. 
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Next, we analyzed TGF-β target gene expression in non-cerebral mouse tissue by quantifying CTGF 
and PAI-1 (plasminogen activator inhibitor-1) mRNA levels in lung, a heavily vascularized organ, and 
aorta, the largest artery of the body. Although in three of the four tissue-target gene combinations 
a trend towards reduced levels in HtrA1-/- mice versus wild-type mice was observed, differences 
were not significant (Figure 3.20).  
 
Figure 3.20: TGF-β target gene expression in lung and aorta samples of HtrA1
-/-
 mice similar to HtrA1
+/+
 mice. Relative 
connective tissue growth factor (CTGF) (A) and plasminogen activator inhibitor-1 (PAI-1) (B) mRNA levels of lung and 
aorta samples isolated from 6 months old HtrA1(tm) animals were determined by real-time PCR (β-Actin was used for 
normalization). Lung: n=7-10; aorta: n=6; results are expressed as mean ±SEM and are not significant as determined by 
Mann-Whitney Rank Sum Test. 
 
In summary, these data indicated decreased TGF-β signaling in HtrA1 knockout mice, an effect 
apparently restricted to brain tissue. 
 
3.4.2 Decreased TGF-β signaling in isolated brain vessels of HtrA1-/- mice 
3.4.2.1 Isolation of brain vessels 
Since CARASIL is a vascular disorder we sought to localize the observed TGF-β signaling alterations 
to cerebral vessels. In collaboration with A. Joutel (University Paris Diderot, France) we established 
a protocol (illustrated in Figure 3.21 A) to isolate microvessels including pial and intraparenchymal 
arteries, veins and capillaries from mouse brains with high purity (see chapter 2.4.6). The quality of 
the preparation was monitored by microscopy (Figure 3.21 B). Depending on the subsequent 
analysis, vessels were processed for mRNA or protein isolation. Figure 3.21 C demonstrates the 
strong enrichment of the vascular SMC marker α-smooth muscle actin (α-SMA) in the preparations. 
The protein yield obtained from different vessel preparations were very low and variable (between 
20 and 90 µg per hemisphere) limiting subsequent analyses. 
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Figure 3.21: Isolation of cerebral microvessels. (A) Schematic diagram of the isolation of vessels from mouse brain. Brain 
material was homogenized with a smooth pestle to leave blood vessels intact. Myelin was removed by Ficoll density 
gradient centrifugation yielding a vessel pellet. Tissue debris still present in this fraction was removed by resuspending 
the pellet and abundant washing on a 40-µm nylon mesh. Purified microvessels were collected by inversion of the mesh. 
The conus depicts a falcon. (B) Microscopic examination of mouse brain vessels without cell debris. (C) α-SMA protein 
levels were analyzed by immunoblotting of 5 µg isolated vessel lysates (two bands on the left side) and 5 µg whole brain 
lysates (two bands on the right side) using an α-SMA antibody (42 kDa). 
 
3.4.2.2 Analysis of TGF-β signaling 
To analyze TGF-β signaling in isolated cerebral vessels, we first investigated the intracellular 
phosphoSMAD2 levels by immunoblotting. In brain vessels of 6 months old HtrA1-/-(tm) mice a 
strong reduction in the phosphoSMAD2 signal compared to wild-type vessels was observed (Figure 
3.22 A). Due to the limited amount of material, equal loading of samples could not always be 
achieved. However, quantification of the phosphoSMAD2 signals and normalization to β-Actin 
levels demonstrated the significance of this observation (Figure 3.22 B). We also performed real-
time PCR studies on mRNA preparations of isolated microvessels. For both analyzed TGF-β target 
genes, CTGF and PAI-1, we observed a significant reduction in vessels from HtrA1-/- mice (Figure 
3.22 C, D) confirming decreased TGF-β signaling as observed by phosphoSMAD2 analysis.  
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Figure 3.22: Reduced TGF-β1 signaling in isolated brain vessels derived from HtrA1
-/-
 mice. (A, B) Phosphorylation of 
SMAD2 in cerebral blood vessels. PhosphoSMAD2 levels were analyzed by immunoblotting of microvessels isolated from 
6 months old HtrA1(tm) mice using a phosphoSMAD2 antibody (A, representative blot) and normalized to β-Actin 
(42 kDa) (B); n=4-6. Relative CTGF (C) and PAI-1 (D) mRNA expression from brain vessels were determined by real-time 
PCR and normalized to β-Actin. n=7-10; results are expressed as mean ±SEM; * p < 0.05 Mann-Whitney Rank Sum Test. 
 
Thus, a reduction of TGF-β pathway activity can specifically be observed in brain microvessels from 
young HtrA1-/- mice (6 months old) confirming our findings from whole brain analysis. Furthermore, 
as for this analysis HtrA1(tm) mice were used, we could demonstrate a decrease of TGF-β signaling 
in the cerebral tissue of two different HtrA1-/- mouse models. 
 
3.4.3 Loss of HtrA1 function results in reduced TGF-β signaling in mouse 
embryonic and human dermal fibroblasts 
To study the effects of HtrA1 deficiency on TGF-β in a homogenous cell population under well-
defined culture conditions, mouse embryonic fibroblasts (MEF) were used, a popular mouse cell 
model (Sharpless, 2006) previously applied to study the TGF-β pathway (Graham et al., 2013, 
Tesseur et al., 2006). Since a serum starvation step, which is detrimental to primary MEF cells, is 
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often required to measure TGF-β effects, we decided to generate MEF cell lines by serial passaging 
and spontaneous immortalization. 
3.4.3.1 Isolation and immortalization of MEF cells 
MEF cells were isolated from 13.5-15.5 days old embryos and propagated in culture (see chapter 
2.5.2). Spontaneous immortalization has been described to occur during serial passaging with high 
frequency resulting from a stochastic genetic event. While the majority of immortalized MEF cell 
loose either the “Guardian of the Genome” p53 (Lane, 1992), or p19ARF function (Kamijo et al., 
1997), various other genetic events can contribute to immortalization (Frank et al., 2000, Jacobs et 
al., 1999, Kamijo et al., 1999, Sharpless et al., 2001). 
Figure 3.23 shows representative growth curves of two HtrA1+/+(gt) and two HtrA1-/-(gt) MEF cell 
lines. Within the first 5-7 passages (15-20 days in culture) cells go through a rapid growth phase, 
before they enter a crisis phase in which they hardly grow or some cells even die. After a lag phase 
(up to 300 days) cultures start to proliferate again, likely due to a few transformed cells 
overgrowing the rest of the culture. In total, we isolated and immortalized seven HtrA1+/+(gt) and 
six HtrA1-/-(gt) MEF cell lines and immortalized one HtrA1+/+(tm) and one HtrA1-/-(tm) MEF cell line.  
 
Figure 3.23: Representative growth curves of two wild-type and two knockout HtrA1(gt) mouse embryonic fibroblast 
lines. Primary HtrA1(gt) MEF cells were isolated from 14.5 days post coitus embryos and immortalized through serial 
replating as described in chapter 2.5.2. The fold proliferation was calculated with the formula: [((number of harvested 
MEF cells)-(number of seeded MEF cells))x100]/(number of seeded MEF cells).  
 
The loss of HTRA1 expression in these lines was confirmed by real-time PCR (Figure 3.24 A). 
Moreover, HtrA1 deficiency could be demonstrated for the first time on protein level. While 
immunoblotting of cell lysates detected a ~50 kDa band in wild-type cells, albeit at low intensity 
(Figure 3.24 B), no signal was observed in HtrA1-/- cells. Even more convincing was the analysis of 
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10-fold concentrated culture medium which revealed a strong, single band confirming expression 
and efficient secretion of HtrA1 in MEF cells. This band was not present in HtrA1-/-(tm) and 
HtrA1-/-(gt) cells demonstrating the absence of HtrA1 in both mouse models. Compared to 
HtrA1+/+(gt) MEF cells, more HtrA1 protein was found in the conditioned medium of HtrA1+/+(tm) 
MEF cells and less in the lysates probably due to variable expression levels between different cell 
lines (see chapter 3.4.4) and unequal HtrA1 ratio in lysate and medium (30 µg whole protein of cell 
lysates were loaded for HtrA1(gt) MEF cells, and only 20 µg were loaded for HtrA1(tm) MEF cells). 
The ~25 and 75 kDa bands in the lysate of HtrA1(tm)+/+ cells likely represent unspecific bands due 
to crossreactivities of the antibody, while the ~30 kDa band in the HtrA1(tm)+/+ cell medium 
probably results from autodegradation. 
 
Figure 3.24: HtrA1 expression in HtrA1
+/+
 and HtrA1
-/-
 MEF cells. (A) Relative mRNA levels from 7 HtrA1
+/+
(gt) and 
6 HtrA1
-/-
(gt) cell lines (left diagram) or 1 HtrA1
+/+
(tm) and 1 HtrA1
-/-
(tm) (right diagram) cell line were determined by 
real-time PCR (right diagrams; used primers: rt-mHtrA1_F and rt-mHtrA1_R). The equal expression of the housekeeping 
gene β-Actin in all cDNA samples guaranteed the correct isolation of RNA and translation to cDNA (data not shown); 
results are expressed as mean ±SEM. (B) Protein levels were analyzed by immunoblotting of 30 µg HtrA1(gt) (left panel) 
or 20 µg HtrA1(tm) (right panel) cell lysates and 20 µl 10-fold concentrated medium using the HtrA1(ΔMac) antibody.  
Results 
69 
Similar to mouse brain tissue, we investigated possible compensatory effects by the HtrA family 
members HtrA3 and HtrA4 using real-time PCR. As observed before, their mRNA expression levels 
were rather reduced than elevated in HtrA1-/- MEF cells (Figure 3.25). 
 
Figure 3.25: HtrA3 and HtrA4 do not compensate for missing HtrA1 on mRNA expression level in MEF cells. HtrA3 and 
HtrA4 mRNA levels of MEF cells isolated from HtrA1(gt) embryos were determined by real-time PCR and normalized to 
β-Actin mRNA levels. n=7-8; results are expressed as mean ±SEM and are not significant as determined by Mann-Whitney 
Rank Sum Test. 
 
Having confirmed HtrA1 deficiency in our MEF cell lines, we turned to the investigation of the 
TGF-β pathway. 
 
3.4.3.2 Decreased TGF-β signaling in HtrA1-/- MEF cells 
In a first step, we quantified TGF-β1 levels in conditioned media collected 48 h after starvation 
from immortalized MEF cell lines using an enzyme-linked immunosorbent assay (ELISA) (see 
chapter 2.5.6 and 2.6.8) and found them significantly reduced to about 50 % in HtrA1-/- medium 
(Figure 3.26 A). In order to correct for cell seeding number variations we normalized total TGF-β 
levels to whole protein amount in the medium and obtained similar results (Figure 3.26 B, values at 
48 h). Moreover, relative TGF-β concentrations in conditioned media collected after different time 
points (24 h, 48 h and 72 h) increased over time in HtrA1+/+ as well as in HtrA1-/- medium and TGF-β 
levels were significantly decreased in HtrA1-/- medium at each time point. 
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Figure 3.26: TGF-β1 protein levels measured via ELISA are decreased in HtrA1
-/-
 MEF cell media. (A) Total TGF-β1 
protein concentrations in pg/ml were determined in supernatants from HtrA1(gt) and HtrA1(tm) MEF cell lines collected 
after 48 h using an ELISA. (B) TGF-β1 protein levels in supernatants from HtrA1(gt) and HtrA1(tm) MEF cell lines collected 
after 24 h, 48 h and 72 h were normalized to whole protein amount in the media. n=7-8; results are expressed as mean 
±SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 Mann-Whitney Rank Sum Test. 
 
Since only a fraction of TGF-β present in body fluids is signaling-competent, we measured bioactive 
TGF-β present in the MEF cell medium by a highly sensitive and specific bioassay. It is based on a 
reporter cell line (MFB-F11) in which the secreted alkaline phosphatase (SEAP) gene is under the 
control of a minimal promoter containing a TGF-β-responsive SMAD binding element (SBE) 
(Tesseur et al., 2006). The line was generated by stable transfection of a secreted alkaline 
phosphatase (SEAP) reporter construct into TGF-β1-/- MEF cells (see chapter 2.5.6 and 2.6.9). Upon 
stimulation with active TGF-β MFB-F11 cells secrete SEAP whose activity can be measured using a 
chemiluminescence assay (Figure 3.27 A). In order to assess the sensitivity and linearity of the 
assay, we stimulated MFB-F11 cells with increasing amounts of recombinant TGF-β1. SEAP activity 
showed a dose-dependent response to TGF-β1 ranging from 1 pg/ml to 1 ng/ml (Figure 3.27 B) 
(Tesseur et al., 2006), a range in which concentration of bioactive TGF-β in MEF media was 
expected (see Figure 3.26 A). Applying this bioassay to MEF cell media conditioned for 48h, we 
detected significantly decreased TGF-β levels in HtrA1-/- MEF cell media compared to wild-type 
media (Figure 3.27 C) even after normalization of SEAP activity to total protein amount present in 
the medium (Figure 3.27 D). Similar results were obtained using the bioassay and MEF media 
collected after 24 h and 72 h (data not shown). 
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Figure 3.27: Reduced TGF-β1 bioactivity in HtrA1
-/-
 MEF cell media. (A) Scheme of a bioassay to measure active TGF-β1. 
Mouse embryonic fibroblasts derived from TGF-β1
-/-
 embryos (MFB-F11) were stably transfected with the reporter 
plasmid pSBE-SEAP consisting of TGF-β responsive SMAD-binding elements (SBE, depicted in light green) coupled to a 
secreted alkaline phosphatase (SEAP, dark green hemicycle) reporter gene (Tesseur et al., 2006). After seeding and 
overnight incubation of MFB-F11 cells, recombinant TGF-β1 (rTGF-β1) or conditioned MEF cell medium was added to 
MFB-F11 cells. SEAP activity was measured after 24 h using a Chemiluminescence kit. (B) TGF-β1 dose-dependently 
induces SEAP reporter activity in MFB-F11 cells. SEAP activity was measured in the conditioned media of MFB-F11 cells 
that were cultured with the indicated concentrations of rTGF-β1. Note the logarithmic scale (C) Conditioned medium 
from HtrA1(gt) and HtrA1(tm) MEF cell lines collected after 48 h activates the TGF-β-responsive reporter cell line 
MFB-F11, inducing expression of alkaline phosphatase activity. (D) SEAP activity in supernatants from HtrA1(gt) and 
HtrA1(tm) MEF cell lines collected after 48 h was normalized to whole protein amount in the media. The relative amount 
of bioactive TGF-β (fold induction) was determined based on the baseline measurement (no TGF-β). n=7-8; results are 
expressed as mean ±SEM; ** p < 0.01 Mann-Whitney Rank Sum Test. 
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To examine intracellular TGF-β pathway activity we analyzed SMAD2 phosphorylation by 
immunoblotting of MEF cell lysates. In HtrA1-/- cells clearly reduced phosphoSMAD2 levels were 
detected (Figure 3.28 A, depicted by a specific ~60 kDa phosphoSMAD2 band). After correction to 
β-Actin, we detected a significant reduction of phosphoSMAD2 levels to ~30 % (Figure 3.28 B), 
while SMAD2 mRNA levels were not different in both MEF cell types (data not shown). 
Finally, we examined the mRNA expression of the TGF-β target genes PAI-1 and CTGF. We observed 
a strong reduction by ~90 % of both mRNA levels in HtrA1-/- MEF cells. While the decrease in PAI-1 
expression was significant, that of CTGF was not due to a large standard deviation 
(Figure 3.28 C, D). It is striking, that in HtrA1-/- cells the target gene mRNA levels are stronger 
reduced than the TGF-β concentration, the TGF-β bioactivity and the phosphoSMAD2 levels. This 
finding results from the fact, that we found large variations between individual MEF cell lines. 
However, as the tendency observed in all assays was the same, we think that these differences are 
not of physiological importance. 
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Figure 3.28: HtrA1 deficiency causes reduced TGF-β1 signaling in MEF cells. (A, B) Phosphorylation of SMAD2 in MEF cell 
lysates. PhosphoSMAD2 levels were analyzed by immunoblotting of MEF cells isolated from HtrA1 mice using a 
phosphoSMAD2 antibody (A, representative blot) and normalized to β-Actin (42 kDa) (B); n=5-7. Relative CTGF (C) and 
PAI-1 (D) mRNA levels from MEF cells were determined by real-time PCR (β-Actin was used for normalization). n=7-8; 
results are expressed as mean ±SEM; * p < 0.05 Mann-Whitney Rank Sum Test. 
 
To rule out that HtrA1-/- MEF cells are for some reasons non-responsive to TGF-β activation, we 
stimulated HtrA1+/+ and HtrA1-/- MEF cells with recombinant TGF-β1 and again analyzed SMAD2 
phosphorylation (Figure 3.29 A) as well as CTGF and PAI-1 mRNA expression levels 
(Figure 3.29 B, C). Although the induction range between the individual cell lines varied strongly 
(see the large SEM bars in Figure 3.29 B; C), we found that each wild-type as well as each knockout 
cell line could be induced upon TGF-β1 stimulation.  
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Figure 3.29: HtrA1
+/+
 and HtrA1
-/-
 MEF cells are induced upon TGF-β1 stimulation. (A) PhosphoSMAD2 levels were 
analyzed by immunoblotting of MEF cells isolated from HtrA1
+/+
(gt) (left panel) and HtrA1
-/-
(gt) (right panel) mice after 
stimulation for 12 h with rTGF-β1 using a phosphoSMAD2 antibody (upper panels). Equal expression of β-Actin 
(lower panels) in all samples guaranteed equivalent loadings. (B) MEF cells were stimulated for 12 h with rTGF-β1 and 
relative CTGF and PAI-1 mRNA levels were determined by real-time PCR (β-Actin was used for normalization). Not-
stimulated cell values were set as 1. n=6-8; results are expressed as mean ±SEM. 
 
These data suggest that HtrA1 deficiency leads to reduced TGF-β signaling in MEF cells. 
 
3.4.3.3 Decreased TGF-β signaling in fibroblasts of CARASIL patients 
The results of TGF-β signaling activity from HtrA1-/- brains and MEF cell cultures contradict 
previously published data on CARASIL patient brains and fibroblasts which indicated elevated 
TGF-β signaling (Hara et al., 2009, Shiga et al., 2011). We therefore used skin fibroblasts from two 
CARASIL patients and analyzed TGF-β target gene mRNA levels. One fibroblast line was derived 
from a 29-year-old Romanian female CARASIL patient carrying compound heterozygous HTRA1 
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mutations: c.961G>A in exon 4 (aa substitution p.A321T) and a G deletion c.126delG in exon 1 
(frameshift p.E42fs; introduction of a stop codon at position 214) (Bianchi et al., 2014). The other 
cell line originated from a 34-year-old Pakistani female CARASIL patient carrying the homozygous 
HTRA1 mutation c.517G>A in exon 2 (aa substitution p.A173T; D. Werring, unpublished). Control 
cells originated from a 45-year-old healthy subject. CTGF mRNA levels were reduced in both 
CARASIL cell lines (Figure 3.30 A). A similar effect was observed for PAI-1 mRNA levels 
(Figure 3.30 B). The homozygous and the compound heterozygous CARASIL cell line varied among 
each other, an effect that was also detected among mouse cell lines derived from animals of the 
same genotype. Thus, level variations do not necessarily have to be attributed to the different 
mutations. However, a clear reduction was observed in both patients compared to the control. 
 
Figure 3.30: TGF-β target gene expression is reduced in fibroblasts derived from CARASIL patients. Relative CTGF (A) 
and PAI-1 (B) mRNA levels from human skin fibroblasts (cell passage numbers: WT/WT p22, p28; A173T/A173T: p15, p20; 
A321T/E42fs: p8, p9) were determined by real-time PCR (β-Actin was used for normalization). WT/WT: control 
fibroblasts; A173T/A173T, A321T/E42fs: CARASIL patient fibroblasts. n=2; results are expressed as mean ±SEM. 
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3.4.4 The HtrA1 substrate LTBP-1 might mediate the effects on TGF-β 
signaling 
Our results showing a reduction of TGF-β activity in mouse tissue and cells as well as CARASIL 
patient cells cannot be explained by processing of previously identified HtrA1 substrates such as 
mature TGF-β, latency-associated peptide (LAP) or TGF-β receptors (Graham et al., 2013, Launay et 
al., 2008, Oka et al., 2004, Shiga et al., 2011), since their cleavage inevitably results in an 
attenuation of TGF-β signaling activity. Work in our group by N. Beaufort had provided evidence for 
an efficient processing of latent TGF-β-binding protein 1 (LTBP-1), an ECM-associated protein 
involved in TGF-β secretion, storage and activation, by purified HtrA1 in vitro. To follow up on this 
finding, we examined the proteolytic activity of wild-type HtrA1 and several mutants expressed in 
the human HEK293T embryonic kidney cell line. 
Initially, we cloned the wild-type HtrA1 into the pcDNA4_TO vector resulting in the in-frame 
attachment of a C-terminal myc/HIS tag. The active site mutation S328A, the two CARASIL 
mutations A252T and V297M and the novel, biochemically uncharacterized G295R variant (Hara et 
al., 2009, Mendioroz et al., 2010) were introduced by site-directed mutagenesis. All HtrA1 
constructs were expressed as ~55 kDa peptides and efficiently secreted upon transient transfection 
into HEK293T cells (Figure 3.31 A). In cells expressing the wild-type protease immunoreactive bands 
of lower molecular weight were detected likely representing autoproteolysis products (Hu et al., 
1998). They could not be observed in any of the mutant-expressing cells indicating reduced 
proteolytic activity. When conditioned cell supernatants of transfected cells were used in a 
proteolysis assay with denatured bovine serum albumin (BSA) as substrate, degradation was only 
observed with wild-type HtrA1 (Figure 3.31 B; see chapter 2.6.7).  
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Figure 3.31: Only wild-type HtrA1 processes its analytical substrate denatured BSA while all HtrA1 constructs are 
expressed and secreted. (A) HEK293T cells were transiently transfected with pcDNA4_TOA plasmid (vec) or plasmids 
containing wild-type (WT), active site mutant (S328A) or CARASIL-mutant (A252T, G295R, V297M) HtrA1 fused to a 
C-terminal myc tag. HtrA1 expression was analyzed by immunoblotting of equal amounts of cell lysates (L) and 
conditioned medium (M) using a myc antibody. (B) Conditioned media from HEK293T cells transiently expressing HtrA1 
variants were incubated with denatured bovine serum albumin (BSA) for 24 h. Samples were analyzed by SDS-PAGE 
followed by staining with CBB solution. Loading BSA without incubation served as a control. 
 
Next, these supernatants were incubated with conditioned HEK293T cell medium containing full-
length (~260 kDa) LTBP-1 and analyzed by immunoblotting: while active-site mutant (S328A) or 
CARASIL-mutant HtrA1 left LTBP-1 mainly unaffected, wild-type HtrA1 completely converted it to a 
stable ~220 kDa cleavage product (Figure 3.32 A). This demonstrated limited proteolysis rather 
than global degradation and suggested site-specific cleavage. Parallel in vitro studies had located 
the cleavage site to the amino-terminal LTBP-1 region and therefore the following experiments 
were performed with a shorter, more stable ~130 kDa C-terminal LTBP-1 deletion variant 
(ΔC-LTBP-1). Processing of ΔC-LTBP-1 was blocked in the presence of the HtrA1-specific inhibitor 
NVP-LBG976 (Grau et al., 2005) from Novartis Pharmaceuticals (HtrA1-I), but not by the 
metalloprotease inhibitor EDTA confirming the specificity of the cleavage (Figure 3.32 B). In order 
to evaluate the effects of HtrA family members HtrA3 and HtrA4, they were likewise overexpressed 
and conditioned supernatants co-incubated with ΔC-LTBP-1-containing medium. Although 
conversion of ΔC-LTBP-1 to a ~90 kDa fragment was also observed with HtrA3 and HtrA4 
conditioned medium, it occurred with less efficiency than with HtrA1 (Figure 3.32 C, upper panel). 
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These results corroborated the data obtained with purified protease and confirmed LTBP-1 as 
promising HtrA1 substrate. 
 
 
Figure 3.32: LTBP-1 is processed by active HtrA proteases. (A) V5 tagged full-length latent TGF-β-binding protein 1 
(LTBP-1)-containing medium was exposed to supernatants from pcDNA4_TOA transfected cells (vec) or from cells 
expressing either wild-type human HtrA1 (WT), active site mutant (S328A) or CARASIL-mutant (A252T, G295R, V297M) 
hHtrA1 fused to a C-terminal myc tag for 24 h. Immunoblotting for LTBP-1 was performed using a V5 antibody (upper 
panel) and for HtrA1 using a myc antibody (lower panel). (B) ∆C-LTBP-1 was exposed to medium from HtrA1 transfected 
cells for 24 h in the absence or presence of an HtrA1 inhibitor (HtrA1-I) or EDTA and immunodetected by anti-V5 (upper 
panel) and anti-HtrA1(ΔMac) (lower panel). (C) Conditioned medium from HEK293T cells transiently expressing mHtrA1-
myc, mHtrA3-myc or mHtrA4-myc was incubated with conditioned medium of V5 tagged ΔC-LTBP-1 for 24 h. Samples 
were analyzed by Western blot using a V5 antibody to detect LTBP-1 (upper panel) or using a myc antibody (lower panel) 
for the HtrA variants. Note, that all HtrA members have slightly different molecular weights due to diverse amino acid 
lengths: calculated molecular weight mHtrA1myc/HIS 54.45 kDa; mHtrA3myc/HIS 52.25 kDa, mHtrA4myc/HIS 55.09 kDa. 
 
In order to examine cleavage by endogenous HtrA1 we used supernatants of our immortalized 
embryonic fibroblasts lines derived from HtrA1+/+ and HtrA1-/- mice. To estimate the molar HtrA1 
concentration present in conditioned MEF media, immunoblotting signals were compared to 
purified HtrA1 as standard. HtrA1 concentrations varying by roughly one order of magnitude were 
detected (5-50 nM; Figure 3.33 and data not shown; supernatants of HtrA1-overexpressing 
HEK293T cells contained concentrations of 50-300 nM, data not shown). Analysis of several 
medium batches taken from different passages indicated a relatively constant expression level 
within one cell line over time (Figure 3.35 A, B and data not shown). As expected, no HtrA1 protein 
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could be detected in lines from HtrA1-deficient embryos. The lower HtrA1 band in WT3(gt), the 
wild-type line with the highest HtrA1 levels, indicated autoproteolysis of endogenous HtrA1. 
 
Figure 3.33: Analysis of HtrA1 expression levels in concentrated HtrA1
+/+
 MEF cell medium. HtrA1 expression was 
evaluated by Western blotting of 10-fold concentrated MEF cell medium using the HtrA1(ΔMac) antibody. Purified, 
recombinant amino-terminally deleted human rHtrA1 (HtrA1-ΔMac; aa 158-480; ~40 kDa; a kind gift from M. Ehrmann, 
University Duisburg-Essen, Germany) served as a standard.  
 
Using supernatants from the WT2(gt), WT3(gt), KO1(gt) and KO2(gt) lines, processing of the 
previously reported substrate TGF-β under endogenous conditions was investigated. Figure 3.34 
shows a representative Western blot of HtrA1+/+ and HtrA1-/- MEF media co-incubated with 
conditioned medium of TGF-β1 transfected cells. In addition to full-length TGF-β1 (pro TGF-β1) the 
processed forms LAP and mature TGF-β were detected. But none of the three peptides showed 
visible degradation upon wild-type medium exposure arguing against their relevance as 
physiological substrates. 
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Figure 3.34: TGF-β1 is not processed by MEF cell-derived HtrA1. Conditioned medium of TGF-β1 transfected cells was 
exposed to concentrated medium derived from HTRA1
+/+
 and HtrA1
-/-
 MEF cell line or DMEM (-) as a control for 72 h and 
immunodetected by anti-TGF-β1 (upper panel), anti-V5 to better visualize mature TGF-β1 (middle panel) and 
anti-HtrA1(ΔMac) (lower panel). 
 
In contrast, efficient processing of LTBP-1 was observed using HTRA1+/+ MEF cell medium indicated 
by the appearance of a cleavage product of LTBP-1 with a molecular weight similar to that 
observed with transfected HtrA1 (Figure 3.35 A). Moreover, a dose-dependent effect between the 
low-expressing line WT1(gt) and the other three lines with higher HtrA1 levels could be detected 
(Figure 3.35 B). No processing was observed with conditioned medium from HTRA1-/- cells. In 
HtrA1+/+ cell medium, processing of LTBP-1 was blocked in the presence of an HtrA1-specific 
inhibitor (HtrA1-I), but not by the metalloprotease inhibitor EDTA (Figure 3.35 C). Similar results 
were obtained with all other MEF cell lines analyzed (data not shown). This indicated that at least 
in MEF cells HtrA1 represents the major LTBP-1-processing protease and overexpressed LTBP-1 is 
cleaved by an endogenous HtrA1 concentration as low as 2.5 nM. 
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Figure 3.35: HtrA1 derived from HtrA1
+/+
 MEF cells processes LTBP-1. (A) Concentrated supernatants from HTRA1
+/+
 and 
HTRA1
-/-
 MEF cell lines were incubated for 72 h with ∆C-LTBP-1 containing medium followed by LTBP-1 (upper panel) and 
HtrA1 (lower panel) immunodetection (used antibody: anti-V5 and anti-HtrA1(16C8)). (B) Media from four different 
HTRA1
+/+
 cell lines and one HTRA1
-/-
 cell line were incubated for 72 h with ∆C-LTBP-1 containing medium followed by 
LTBP-1 (upper panel) and HtrA1 (lower panel) immunodetection (used antibody: anti-V5 and anti-HtrA1(ΔMac)). (C) ∆C-
LTBP-1 was exposed to concentrated medium derived from the HTRA1
+/+
 MEF cell line WT3(gt) for 48 h at 37 °C in the 
absence or presence of an HtrA1 inhibitor (HtrA1-I) or EDTA and immunodetected by anti-V5 (upper panel) and anti-
HtrA1(ΔMac) (lower panel). 
 
In summary, it could be shown that, in contrast to CARASIL-mutant HtrA1, the wild-type protease 
processed LTBP-1 even under endogenous conditions, an observation that was not detected with 
the formerly proposed substrate TGF-β. 
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4 Discussion 
Small vessel disease (SVD) accounts for ~20 % of all strokes and is a leading cause of cognitive 
decline and disability in adults worldwide (Pantoni, 2010). However, therapeutic options are 
limited compared to other common causes of stroke mainly due to a poor understanding of the 
disease pathogenesis. Monogenic inherited SVDs such as CARASIL resemble non-Mendelian forms 
on neuropathological and clinical level suggesting shared pathomechanisms. They are thus 
considered valuable model diseases to identify factors suitable for the development of novel 
treatment strategies. CARASIL is caused by homozygous mutations in the HTRA1 gene, coding for 
the secreted serine protease high temperature requirement A1 (HtrA1) (Hara et al., 2009). 
Mutations either locate within the catalytic domain leading to a strong reduction in protease 
activity or result in nonsense-mediated mRNA decay. Thus, CARASIL likely develops as a 
consequence of a loss of HtrA1 function. In the present study we provide further support for this 
hypothesis by demonstrating strongly decreased proteolytic activity of the biochemically previously 
uncharacterized HtrA1 mutation G295R (Mendioroz et al., 2010). Similarly, the A173T mutation 
present in the patient skin fibroblasts used in this work was also shown to be proteolytically 
inactive (N. Beaufort, personal communication). While G295R like the majority of CARASIL 
mutations resides within the catalytic domain and possibly alters its three-dimensional structure, 
A173T locates within the preceding linker region. The underlying basis for its loss-of-function effect 
is yet unknown. 
 
4.1 Characterization of HtrA1-/- mice 
Gene ablation in mice was chosen as an approach to mimic loss of HtrA1 in vivo. At the beginning 
of this thesis, a novel HtrA1-deficient mouse strain was generated from embryonic stem cells 
harboring an HTRA1 allele interrupted by gene trapping (gt). This strain was used for the majority 
of experiments, but contained a mixed genetic background of 129/SvEvBrd and C57BL/6J. At a later 
time point a second HtrA1 knockout strain generated by conventional targeted mutagenesis (tm) 
(Jones et al., 2011, Zhang et al., 2012) and containing a 98-99 % homogenous C57BL/6J background 
became available. Variations in the genetic background may influence the penetrance or severity of 
phenotypic features including alopecia (Sundberg et al., 1994), a major symptom of CARASIL 
patients. Thus, analysis of the extraneurological manifestations alopecia and spondylosis was 
performed in the HtrA1(tm) strain. The lack of HtrA1 expression was initially verified on mRNA level 
in both strains. During the course of this work we succeeded in generating a monoclonal anti-HtrA1 
antibody and got access to a polyclonal antiserum (Vierkotten et al., 2011). Using these antibodies 
the absence of HtrA1 in both mouse strains could be verified on protein level. 
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HtrA1 knockout mice are viable and fertile, which is in agreement with the lack of lethality in 
humans. However, in contrast to patients, HtrA1-/- mice have a normal life expectancy and display 
no obvious disease symptoms. This includes the lack of alopecia and spondylosis. However, their 
relevance for the disease is unclear as for example not all CARASIL patients display signs of alopecia 
(Nozaki et al., 2014). It is possible that in humans these symptoms develop due to HtrA1 substrates 
different from those mediating neurological deficits. These substrates might well be part of cellular 
pathways whose impairment cannot be adequately recapitulated in mice. To rule out that 
compensatory mechanisms involving other HtrA1 family members might be responsible for the lack 
of these CARASIL symptoms in mice, we analyzed HtrA3 and HtrA4 mRNA expression levels, but no 
significant increase was observed. 
In contrast, analysis of neurological features indeed revealed differences in HtrA1 knockout and 
wild-type mice. Within white matter diffuse demyelination was observed, a symptom also present 
in CARASIL patients. The histological analysis of brain vessels revealed a reduction of α-smooth 
muscle actin (α-SMA) in HtrA1-deficient mice reminiscent of the smooth muscle cell (SMC) loss 
observed in CARASIL patients (Fukutake, 2011, Oide et al., 2008). Interestingly, this loss was 
detected only in aged animals possibly reflecting the progressive nature of the disease. Moreover, 
decreased type IV collagen expression as reported in patients (Oide et al., 2008) was also detected 
in HtrA1-/- mouse brains. 
In a mouse model for CADASIL, another monogenic SVD showing considerable phenotypic overlap 
with CARASIL, Joutel et al. (2010) reported increased cerebral glial fibrillary acidic protein (GFAP) 
expression as a marker for neurodegeneration. Upon investigation of HtrA1-/- mouse brains, we did 
not detect such an effect (data not shown). In addition, we were unable to demonstrate a higher 
number of white matter lesions as described for the CADASIL mouse model (Joutel et al., 2010). 
This might be explained by a lower severity of pathology in HtrA1-deficient compared to CADASIL 
mice. Moreover, the strain background which can be decisive for the development of a phenotype 
(Gould et al., 2006) might play a role. It has been shown, that 129/SvEvBrd mice are less 
susceptible to ischemic injury than C57BL/6 mice (Hara et al., 1996). Thus, the partial 129/SvEvBrd 
background of the HtrA1(gt)-/- strain might ameliorate the neurological damage. 
Nevertheless, the observed alterations in white matter structure and cerebral vessel morphology 
indicated that HtrA1-deficient mice at least partially recapitulate CARASIL pathology. We therefore 
proceeded by analyzing the consequences of HtrA1 deficiency on transforming growth factor beta 
(TGF-β) signaling. 
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4.2 HtrA1 and TGF-β signaling 
4.2.1 HtrA1 deficiency reduces TGF-β signaling 
Previous studies had suggested a link between HTRA1 mutations and impaired TGF-β signaling 
mediated by reduced cleavage of mature TGF-β, proTGF-β or TGF-β receptors TGFBRII and TGFBRIII 
(Graham et al., 2013, Hara et al., 2009, Launay et al., 2008, Oka et al., 2004, Shiga et al., 2011). To 
better define the mechanistic relationship between HtrA1 and TGF-β, we investigated 
HtrA1-deficient mice with respect to TGF-β at various levels including SMAD2 phosphorylation and 
expression of the target genes CTGF and PAI-1. Initially, we analyzed whole brain tissue and 
surprisingly observed a down-regulation of TGF-β activity, a finding being in contrast to previously 
reported data from CARASIL patients (Hara et al., 2009, Shiga et al., 2011). 
Therefore, we set out to verify our findings using additional approaches. First, we established a 
method to isolate microvessels from mouse brain resulting in the removal of parenchymal tissue. 
Again, we observed reduced TGF-β signaling on phosphoSMAD2 and TGF-β target gene level 
demonstrating TGF-β dysregulation in the vasculature of HtrA1-deficient mice. This finding is in 
agreement with the severe vascular phenotype in CARASIL patients and supported our results 
obtained in whole-brain tissue. The availability of purified microvessels opens new possibilities for 
future biochemical studies of HtrA1 deficiency. For example transcriptome and proteome analyses 
of this material might help to elucidate details of the molecular mechanisms underlying CARASIL 
development. 
To confirm the effects on TGF-β activity at cellular level mouse embryonic fibroblast (MEF) cell lines 
were generated. In HtrA1-deficient lines the reduction of SMAD2 phosphorylation as well as CTGF 
and PAI-1 expression was confirmed. In addition, levels of total and bioactive TGF-β could be 
evaluated in conditioned fibroblast media and again a significant decrease in HtrA1-/- MEF cells was 
measured. TGF-β concentrations could not be determined in tissue lysates as they were below the 
detection limit likely due to the short half-life of TGF-β in tissues (Kaminska et al., 2005). However, 
TGF-β levels were detectable in blood serum, but no significant differences between 
HtrA1-deficient and control mice were observed. Also CTGF and PAI-1 mRNA levels in lung and 
aorta tissue did not differ significantly excluding a systemic TGF-β dysregulation. The 
extraneurological symptoms observed in CARASIL patients might be caused by an impairment of 
TGF-β family members other than TGF-β itself (e.g. bone morphogenetic proteins) or by the lack of 
processing of alternative HtrA1 substrates. In summary, our results from mouse tissues and cells 
clearly suggested a reduction of TGF-β signaling under HtrA1-deficient conditions. 
To investigate whether the discrepancy between our data and published findings in CARASIL 
patients might be due to species-specific differences, we used primary skin fibroblasts from two 
CARASIL subjects, a 29-year-old Romanian female being compound heterozygous for the HTRA1 
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mutations A321T and E42fs (Bianchi et al., 2014) and a 34-year-old Pakistani female homozygous 
for the A173T mutation (D. Werring, unpublished). Applying the various assays described before 
(TGF-β concentration and bioactivity, SMAD2 phosphorylation, CTGF and PAI-1 expression), we 
demonstrated a decrease in activity in both cell lines (Beaufort et al., 2014). The presence of this 
observation in two unrelated patient cell lines carrying different HTRA1 mutations argued for the 
specificity of this finding. Moreover, skin fibroblasts derived from the heterozygous parents of the 
CARASIL patient with the compound heterozygous A321T/E42fs mutation displayed PAI-1 and CTGF 
mRNA levels in between those derived from patient and control fibroblasts (data not shown) 
arguing for the reliability of our measurements. 
Even though HtrA1-/- mice and CARASIL patient fibroblasts do not cover all clinical and molecular 
aspects of CARASIL, we nevertheless consider the consistency of the results obtained from two 
different species as convincing evidence for their disease relevance. 
 
4.2.2 Controversial findings concerning deregulated TGF-β signaling and 
loss of HtrA1 
Our findings contrast with previous studies, which reported an up-regulation of TGF-β signaling in 
CARASIL brains as demonstrated by an increase in TGF-β, phosphoSMAD2, hyaluronan, fibronectin 
(extra domain-A) and versican (Hara et al., 2009, Shiga et al., 2011). TGF-β promotes the expression 
of extracellular matrix (ECM) components and represents a key mediator of fibrosis. Thus, it cannot 
be excluded that increased TGF-β activity reflects fibrotic changes of blood vessels in advanced 
CARASIL disease stages. In addition, the reported data were restricted to two autopsy cases with 
limited information on histopathological samples and individual differences with respect to TGF-β 
signaling cannot be ruled out. Moreover, increased TGF-β in the cerebrovasculature of CARASIL 
patients might be explained by the observation that TGF-β signaling is up-regulated after stroke 
(Doyle et al., 2010). Our mouse model allows the investigation of early disease stages and 
decreased TGF-β signaling was detected already in young knockout animals. With respect to 
published data in patient fibroblasts, mRNA levels of the TGF-β target gene Noggin were found to 
be elevated only in cells from a single patient (Hara et al., 2009). However, the presented data 
might be difficult to interpret since the Noggin gene contains only one exon and real-time PCR 
signals might thus also originate from residual genomic DNA present in the RNA sample.  
Very recently, Graham et al. (2013) demonstrated an increase of TGF-β target gene expression in 
MEF cells derived from a third HtrA1 knockout mouse model with a targeted gene deletion of 
HTRA1. However, results were obtained with cells stimulated by recombinant TGF-β and 
furthermore, it was not clear whether they used only technical or also individual replicates. 
Performing this experiment under identical conditions, we did not observe a change in CTGF and 
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PAI-1 expression levels using 6-8 different embryonic cell lines per genotype derived from our 
mouse models (see Figure 3.29). Even though we detected differences among individual cell lines 
of the same genotype (see high error bars in Figure 3.29), we did not find significant differences 
between wild-type and knockout MEF cells. Though, in line with their data, Graham et al. (2013) 
demonstrated a slight but significant increase of bone volume and trabecular thickness in the distal 
femurs and the vertebrae by using microcomputed tomography (µCT), an effect possibly mediated 
by elevated TGF-β activity. This contrasts with our X-ray or µCT analysis which did not reveal 
abnormalities in HtrA1 knockout mice. Differences in the genetic background of the used mouse 
strains might be responsible for these discrepancies.  
In order to address the different effects of a loss of HtrA1 function on TGF-β signaling on a 
molecular level, we started to investigate the relationship between HtrA1 and TGF-β in vitro. Under 
overexpression conditions and upon co-transfection, we detected an extracellular as well as 
intracellular degradation of TGF-β1 by wild-type HtrA1 (data not shown). However, mature and pro 
TGF-β were not processed by endogenous HtrA1 suggesting that they do not represent biologically 
relevant substrates. Previous studies claiming the identification of TGF-β as a substrate had 
primarily used purified or overexpressed HtrA1 (Launay et al., 2008, Shiga et al., 2011) raising 
doubts about the specificity of the observed effects. In addition, latency associated peptide (LAP) 
degradation (Shiga et al., 2011) was observed in the endoplasmic reticulum where proteases 
accumulate upon strong overexpression. We therefore had started to search for alternative HtrA1 
substrates and during the course of this thesis latent TGF-β-binding protein (LTBP-1) had emerged 
as a promising candidate (Beaufort et al., 2014). LTBP-1 represents an ECM protein that mediates 
the sequestration of latent TGF-β. At physiological concentrations as low as 1 nM (An et al., 2010) 
HtrA1 had been shown to process LTBP-1 into a stable truncated fragment which no longer 
incorporates into the ECM (Beaufort et al., 2014). Within this thesis the lack of LTBP-1 cleavage in 
the presence of CARASIL mutant HtrA1 could be shown. To demonstrate LTBP-1 processing by 
endogenous HtrA1, conditioned supernatants of the various MEF cell lines generated in this study 
were used. Treatment of purified LTBP-1 with supernatants from wild-type lines indeed resulted in 
an HtrA1 dose-dependent cleavage and in a fragment similar to that observed with purified or 
overexpressed HtrA1. Moreover, processing was not seen when supernatants from HtrA1-deficient 
cell lines or from wild-type cell lines in the presence of a specific HtrA1 inhibitor were used. This 
suggested that, at least in MEF cells, HtrA1 is the predominant LTBP-1 cleaving protease strongly 
supporting the physiological relevance of LTBP-1 processing by HtrA1. 
To examine whether other LTBP family members might also be subject to HtrA1-mediated 
processing we performed in vitro cleavage assays with LTBP-4- and HtrA1-containing supernatants 
and observed also a reduction of full-length LTBP-4 (data not shown). Hence, HtrA1 might regulate 
the function of LTBP proteins in general. 
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Site-specific LTBP-1 proteolysis followed by its dissociation from the ECM resulting in TGF-β release 
and activation has been described before (Dallas et al., 1994, Ge and Greenspan, 2006, Taipale et 
al., 1994, Tatti et al., 2008). Moreover, bone morphogenetic protein 1 (BMP-1)-mediated cleavage 
of LTBP-1 was reported to result in reduced TGF-β activity in BMP-1 knockout MEF cells (Ge and 
Greenspan, 2006). Upon HtrA1-mediated cleavage we observed decreased LTBP-1 incorporation 
into the ECM, and in HtrA1-deficient fibroblasts as well as cerebral tissues we detected reduced 
TGF-β signaling. Thus, we propose that HtrA1-mediated LTBP-1 processing results in a release of 
mature TGF-β from the ECM and, as a consequence, in excessive TGF-β signaling (Figure 4.1). In the 
absence of HtrA1, LTBP-1 cleavage is abolished leading to decreased TGF-β activity. Molecular 
details of the process how HtrA1-mediated LTBP-1 degradation facilitates TGF-β signaling remain to 
be elucidated. 
 
 
Figure 4.1: Lack of HtrA1 in mouse brain leads to reduced LTBP-1 processing and subsequently to decreased TGF-β 
signaling. Schematic representation of the consequences of HtrA1 deficiency on transforming growth factor beta (TGF-β) 
pathway in mouse brain. See text for details. ECM: extracellular matrix; LAP: latency associated peptide; mat. TGF-β: 
mature form of TGF-β; LTBP-1: latent TGF-β binding protein. 
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4.2.3 Deregulated TGF-β as a key mechanism involved in vascular diseases 
Our findings add to current evidence suggesting a role of the TGF-β signaling pathway for normal 
vascular function. It is known, that mutations in components of the TGF-β pathway as well as its 
interacting partners mediating TGF-β sequestration into the ECM result in severe vascular defects. 
For instance, TGF-β signaling was demonstrated to be enhanced in Marfan syndrome (MFS), which 
is characterized by aortic root aneurysms and dissections. MFS is caused by mutations in FBN1 
encoding the ECM component fibrillin-1 (Dietz et al., 1991). Furthermore, Loeys-Dietz syndrome 
(LDS), a hereditary condition with considerable phenotypic overlap with MFS also results in severe 
vascular defects. LDS is caused by loss-of-function mutations in TGFBRI and II (Loeys et al., 2005), 
SMAD3 (van de Laar et al., 2011) or TGFB2 (Lindsay et al., 2012). Whereas all mutations are 
predicted to result in a down-regulation of TGF-β activation, surprisingly an up-regulation was 
detected in the aortic wall of patients as well as LDS mouse models. Several mechanisms have been 
proposed for this paradox phenomenon: due to mutations in the canonical components TGFBR1/2, 
SMAD3 or TGFB2 of the TGF-β signaling pathway, the non-canonical pathway (ERK/mitogen-
activated protein kinase) might overcompensate for the missing canonical pathway (Holm et al., 
2011, Li et al., 2014). Moreover, it has been suggested, that a shift from TGFB2-driven to TGFB1-
driven signaling occurs in TGFB2-deficient patients and mice (Lindsay et al., 2012). An additional 
disease involving deregulated TGF-β signaling as a pathogenic mechanism is hereditary 
hemorrhagic telangiectasia (HHT), an autosomal dominant vascular disorder characterized by 
fragile blood vessels leading to telangiectasia and arteriovenous malformations (McAllister et al., 
1994). HHT is caused by heterozygous mutations in the genes encoding the TGF-β pathway 
members ENG (endoglin), ACVRL1 (activin receptor-like kinase 1) or SMAD4 (ten Dijke and Arthur, 
2007). In contrast to LDS- and MFS-mutations, HHT-mutations result in down-regulated TGF-β 
signaling (Letarte et al., 2005). Even though pathomechanisms involving down-regulation of TGF-β 
pathway are very rare, it is known, that a complete TGFB1 knockout in mice leads to embryonic 
lethality with severe vascular defects or postnatal lethality from autoimmune disease (Dickson et 
al., 1995, Shull et al., 1992). Similar effects were reported for TGF-β2 and TGF-β3 knockout mice 
(Goumans and Mummery, 2000). Thus, loss of TGF-β or even reduction of TGF-β signaling has 
serious consequences for the vasculature in mice as well as humans. 
Transforming growth factor beta (TGF-β) is known to induce expression of components of the ECM 
and other genes regulating the composition of the ECM (ten Dijke and Arthur, 2007) including type 
IV collagen (Grande et al., 1993). Thus, decreased type IV collagen expression found in the cerebral 
vasculature of CARASIL patients as well as HtrA1 knockout mice might be mediated by reduced 
TGF-β expression. Very likely, expression levels of other ECM proteins are also reduced leading to 
an abnormal composition of the ECM. Furthermore, it has been shown, that TGF-β1-/- mice show 
uncompact myelin (Day et al., 2003). Thus, diffuse white matter changes might result from 
deregulated TGF-β signaling in HtrA1-deficient mice and patients.  
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Interestingly, recent studies indicate that dysregulation of the TGF-β pathway is also involved in 
CADASIL development, another monogenic form of SVD. It is caused by mutations in the cell 
surface receptor Notch3 and characterized by aggregates containing the extracellular domain (ECD) 
of Notch3 in brain vessels walls. These aggregates might promote pathological processes leading to 
vessel dysfunction by recruiting extracellular proteins including ECM components (Monet-Lepretre 
et al., 2013). A study from our group investigated the details of this process and observed an 
accumulation of LTBP-1 protein in CADASIL-affected vessel walls (Kast et al., 2014). Moreover, an 
almost perfect co-localization with Notch3 suggested LTPB-1 as a constituent of Notch3 aggregates. 
Also a direct interaction of LTBP-1 with Notch3-ECD and a co-aggregation with mutant Notch3 in 
vitro could be demonstrated. Finally, evidence for increased levels of the TGF-β pro-domain in 
CADASIL patient vessels was provided. Since CADASIL shares the main clinical features with 
CARASIL, it seems likely that a dysregulation of TGF-β signaling represents a common feature in 
both diseases. 
In conclusion, our findings provide a new and unexpected link between TGF-β pathway and 
CARASIL which might also be of relevance for other hereditary and even the more common forms 
of cerebral SVD. 
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8 Abbreviations 
°C centigrade 
α-SMA α-smooth muscle actin 
aa amino acid 
BMP bone morphogenetic protein 
bp base pairs 
BSA bovine serum albumin  
CARASIL cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy 
CBB coomassie brilliant blue  
cDNA complementary deoxyribonucleic acid  
Ct cycle threshold 
C-terminal carboxy-terminal  
CTGF connective tissue growth factor  
ΔC carboxy-terminal deletion 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco's Modified Eagle Medium  
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid  
dNTP deoxynucleoside triphosphate 
DTT dithiothreitol 
E. coli Escherichia coli 
ECM extracellular matrix  
ELISA enzyme-linked immunosorbent assay  
et al. et alii (and others) 
FBS fetal bovine serum 
fs frameshift 
g gram or earth´s gravity 
GOM granular osmiophilic material 
gt gene trap 
h hour(s) 
H2ODI  deionized water 
HEK human embryonic kidney  
HRP horseradish peroxidase  
HtrA high temperature requirement A 
HtrA1-I HtrA1 inhibitor 
kDa kilodalton 
KO knockout 
l liter 
LB Luria-Bertani  
LTBP latent TGF-β-binding protein  
µ micro 
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m milli 
M molar 
MEF mouse embryonic fibroblasts 
MFS Marfan syndrome  
min minute(s) 
MRI magnetic resonance imaging  
mRNA messenger ribonucleic acid 
n nano 
NEO neomycin 
N-terminal amino-terminal (of a protein) 
PAGE polyacrylamide gel electrophoresis  
PAI-1 plasminogen activator inhibitor-1 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PI protease inhibitor(s) 
r recombinant 
RNA ribonucleic acid 
s second(s) 
SBE SMAD binding element  
SDS sodiumdodecylsulfate 
SEAP secreted alkaline phosphatase 
SMAD from Sma and Mad (Mothers against decapentaplegic)  
SMCs smooth muscle cells 
SVD small vessel disease 
TGFBR TGF-β receptor 
TGF-β transforming growth factor beta 
tm targeted mutation 
vec vector 
vSMCs vascular smooth muscle cells 
w/v mass/volume 
WM white matter 
WT wild-type 
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